WO2010147612A1 - Methods of modulating cell regulation by inhibiting p53 - Google Patents
Methods of modulating cell regulation by inhibiting p53 Download PDFInfo
- Publication number
- WO2010147612A1 WO2010147612A1 PCT/US2010/000279 US2010000279W WO2010147612A1 WO 2010147612 A1 WO2010147612 A1 WO 2010147612A1 US 2010000279 W US2010000279 W US 2010000279W WO 2010147612 A1 WO2010147612 A1 WO 2010147612A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- alkyl
- compound
- alkenyl
- alkynyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 97
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 13
- 230000009134 cell regulation Effects 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 70
- 230000008569 process Effects 0.000 claims abstract description 58
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 31
- 229940122454 Protein phosphatase 2A inhibitor Drugs 0.000 claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 230000008672 reprogramming Effects 0.000 claims abstract description 19
- 230000001965 increasing effect Effects 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 214
- 125000000217 alkyl group Chemical group 0.000 claims description 111
- 125000003342 alkenyl group Chemical group 0.000 claims description 81
- 150000003839 salts Chemical class 0.000 claims description 71
- 125000000304 alkynyl group Chemical group 0.000 claims description 59
- 125000003118 aryl group Chemical group 0.000 claims description 52
- 125000001424 substituent group Chemical group 0.000 claims description 42
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 35
- 125000003107 substituted aryl group Chemical group 0.000 claims description 35
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 29
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000004069 aziridinyl group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 4
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 3
- 230000000392 somatic effect Effects 0.000 claims description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 1
- 229940125758 compound 15 Drugs 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 42
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 24
- 230000000694 effects Effects 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 16
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 14
- 229960004964 temozolomide Drugs 0.000 description 14
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 10
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 10
- 102000007469 Actins Human genes 0.000 description 8
- 108010085238 Actins Proteins 0.000 description 8
- 101710157927 Translationally-controlled tumor protein Proteins 0.000 description 8
- 102100029887 Translationally-controlled tumor protein Human genes 0.000 description 8
- 239000006166 lysate Substances 0.000 description 8
- -1 pMDM2 Proteins 0.000 description 8
- WZXXZHONLFRKGG-UHFFFAOYSA-N 2,3,4,5-tetrachlorothiophene Chemical compound ClC=1SC(Cl)=C(Cl)C=1Cl WZXXZHONLFRKGG-UHFFFAOYSA-N 0.000 description 7
- 101710175870 Translationally-controlled tumor protein homolog Proteins 0.000 description 7
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 7
- 0 CN1CC*CC1 Chemical compound CN1CC*CC1 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 4
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 2
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 2
- SCDBMVUYZQADGP-UHFFFAOYSA-N CNC1CCN(CCc(cc2)ccc2OC)CC1 Chemical compound CNC1CCN(CCc(cc2)ccc2OC)CC1 SCDBMVUYZQADGP-UHFFFAOYSA-N 0.000 description 2
- 101100322915 Caenorhabditis elegans akt-1 gene Proteins 0.000 description 2
- 239000012623 DNA damaging agent Substances 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 2
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000005189 alkyl hydroxy group Chemical class 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- FSVKYRMQMBEVNC-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(c1c(cc2)[o]c2c1C(O)=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(c1c(cc2)[o]c2c1C(O)=O)=O)=O FSVKYRMQMBEVNC-UHFFFAOYSA-N 0.000 description 1
- HVOYZOQVDYHUPF-UHFFFAOYSA-N CNCCN(C)C Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical class O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000017205 mitotic cell cycle checkpoint Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 150000004707 phenolate Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Definitions
- iPS pluripotent stem cells
- a method of inhibiting the function of p53 in a cell comprising contacting the cell with an effective amount of a PP2A inhibitor, wherein the PP2A inhibitor is a compound having the structure:
- R 3 and R 4 are each different, and each is OH, 0 ⁇ , OR 9 , OR 10 , O(CH 2 )i_ 6 R 9 , SH, S ' , SR 9 ,
- each Ri 2 is independently alkyl, alkenyl or alkynyl, each of which is substituted or -unsubstituted, or H;
- R 1O is substituted alkyl, substituted alkenyl, substituted alkynyl, or substituted aryl;
- R 7 and R 8 is each independently H, F, Cl, Br, SO 2 Ph, CO 2 CH 3 , or SR 13 , where R 13 is H, aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl, or a salt, enantiomer or zwitterion of the compound, so as to thereby inhibit the function of p53 in the cell.
- a process for producing an induced pluripotent stem (iPS) cell comprising contacting a somatic cell expressing at least one gene that encodes a reprogramming factor with an amount of a PP2A inhibitor effective to produce the iPS cell.
- a process for reversibly inhibiting p53 function during production of an induced pluripotent stem (iPS) cell from a somatic cell expressing at least one gene that encodes a reprogramming factor comprising contacting the somatic cell with an amount of a PP2A inhibitor effective to reversibly inhibit p53 function.
- iPS induced pluripotent stem
- iPS induced pluripotent stem
- the process for production of the iPS cells comprises transforming a population of somatic cells with at least one gene that encodes a reprogramming factor, the process comprising contacting the population of somatic cells with an amount of a PP2A inhibitor effective to increase the efficiency of the production of iPS cells.
- iPS induced pluripotent stem cell
- Figure 2 Inhibition Of PP2A Activity In U87 Subcutaneous (sc) Xenografts and In Normal Brain Tissue.
- FIG. 3 Cellular and Molecular Changes in U87 Cells Induced By Compound 102.
- Figure 4 p53, pMDM2 and ⁇ -actin After Exposure To Compound 102.
- FIG. 5 Western Blots of p-Akt-1, p53, pMDM2 and ⁇ -actin In Lysates of U87 Cells.
- TMZ Temozolomide
- Figure 6 Western Blots of p-Akt-1, p53, and ⁇ -actin In Lysates of U373 Cells.
- the invention provides a method of inhibiting the function of p53 in a cell comprising contacting the cell with an effective amount of a PP2A inhibitor, wherein the PP2A inhibitor is a compound having the structure:
- R 3 and R 4 are each different, and each is OH, 0 " , OR 9 , ORi 0 ,
- each Ri 2 is independently alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H;
- Rio is substituted alkyl, substituted alkenyl, substituted alkynyl, or substituted aryl;
- R 7 and R 8 is each independently H, F, Cl, Br, SO 2 Ph, CO 2 CH 3 , or SRi 3 , where R 13 is H, aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl, or a salt, enantiomer or zwitterion of the compound, so as to thereby inhibit the function of p53 in the cell.
- the compound has the structure
- the compound has the structure
- the compound is compound 104, compound 104E, compound 106, or compound 106E; or a salt, enantiomer or zwitterion of the compound.
- the compound has the structure
- bond ⁇ is present or absent; Rg is present or absent and when present is H, Ci-C 10 alkyl, C 2 -C 10 alkenyl or phenyl; and X is 0, S, NR 11 or N + R 11 R n , where each R 11 is independently H, alkyl, substituted C 2 -C 12 alkyl, alkenyl, substituted C 4 -C 12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
- the compound has the structure
- bond a. is present or absent
- X is O, S, NRn or N + RnRn, where each Rn is independently H, alkyl, substituted C 2 -Ci 2 alkyl, alkenyl, substituted Cj-Ci 2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
- the compound has the structure
- Rg is present or absent and when present is H, alkyl, alkenyl, alkynyl or phenyl;
- X is 0, NRn, or N + RnRi 1 , where each Rn is independently H, alkyl, substituted C 2 -Ci 2 alkyl, alkenyl, substituted C 4 - Ci 2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
- R 12 is H or alkyl, or a salt, zwitterion, or enantiomer of the compound.
- the compound has the structure
- X is 0 or NH + Rn, where Rn is H, alkyl, substituted C 2 -C 12 alkyl, alkenyl, substituted C4-C1 2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
- R i2 is H or alkyl, or a salt, enantiomer or zwitterion of the compound.
- bond ⁇ is present.
- bond a is absent.
- the compound has the structure of compound 100, compound 102, compound 101, compound 103, compound 105, or compound 107; or a salt, entantiomer or zwitterions of the compound.
- the compound has the structure of compound 10OE, compound 102E, compound 101E, compound 103E, compound 105E, or compound 107E; or a salt, entantiomer or zwitterions of the compound.
- the compound has the structure
- bond ⁇ is present or absent;
- X is NH + Rn, where Rn is present or absent and when present Rn is al kyl , substituted C 2 -Ci 2 al kyl , al kenyl , substituted C 4 -Ci 2 al kenyl ,
- R 12 is H or alkyl, or a salt, enantiomer or zwitterion of the compound
- the compound is compound 108 or a salt enationmer or zwitterions of the compound.
- R 3 is ORio or 0 (CH 2 ) i- 6 R 9 , where R 9 is aryl or substituted ethyl; where R i0 is substituted phenyl, wherein the substituent is in the para position;
- Rn is independently H, alkyl, hydroxyalkyl, substituted C 2 -Ci 2 alkyl, alkenyl, substituted C 4 -Ci 2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
- Ri 2 is alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H; or where R 3 is OH and R 4 is
- the compound has the structure where Rn is alkyl or hydroxylalkyl or R 4 is
- the compound when R 3 is OH, or a salt, enantiomer or zwitterion of the compound,
- the compound has the structure of compound 109, compound 110, compound 112, compound 113, or compound 114; or a salt, enantiomer or zwitterion of the compound.
- the compound has the structure of compound 109E, compound HOE, compound 112E, compound 113E or compound 114E; or a salt enatniomer or zwitterion of the compound.
- the comound 108E or compound 111 or a salt enatniomer or zwitterion of the compound.
- This invention further provides a process for producing an induced pluripotent stem (iPS) cell comprising contacting a somatic cell expressing at least one gene that encodes a reprogramming factor with an amount of a PP2A inhibitor effective to produce the iPS cell.
- iPS induced pluripotent stem
- Also provided is a process for reversibly inhibiting p53 function during production of an induced pluripotent stem (iPS) cell from a somatic cell expressing at least one gene that encodes a reprogramming factor comprising contacting the somatic cell with an amount of a PP2A inhibitor effective to reversibly inhibit p53 function.
- iPS induced pluripotent stem
- This invention further provides a process for increasing the likelihood of producing an induced pluripotent stem (iPS) cell comprising contacting a somatic cell expressing at least one gene that encodes a reprogramming factor with an amount of a PP2A inhibitor effective increa the likelihood of producing an iPS.
- iPS induced pluripotent stem
- This invention also provides a process for increasing the production efficiency of induced pluripotent stem (iPS) cells, wherein the process for production of the iPS cells comprises transforming a population of somatic cells with at least one gene that encodes a reprogramming factor, the process comprising contacting the population of somatic cells with an amount of a PP2A inhibitor effective to increase the efficiency of the production of iPS cells.
- iPS induced pluripotent stem
- This invention further provides a process of producing an induced pluripotent stem cell (iPS) comprising transforming a somatic cell to express at least one gene that encodes a reprogramming factor such that the somatic becomes an iPS, wherein the improvement comprises contacting the somatic cell with an amount of a PP2A inhibitor effective to transiently reduce the function of p53 in the cell.
- iPS induced pluripotent stem cell
- the PP2A inhibitor is a compound having the structure:
- R 3 and R 4 are each different, and each is OH, 0 " , ORg, ORi 0 , 0 (CH 2 ) i- ⁇ Rg, SH, S " , SR 9 ,
- the compound has the structure
- the compound has the structure
- R 4 is
- the compound is in another embodiment of the above processes, the compound is in a further embodiment, the compound is compound 104, compound 104E, compound 106, or compound 106E; or a salt, enantiomer or zwitterion of the compound.
- the compound has the structure
- the compound has the structure
- bond ⁇ is present or absent
- X is 0, S, NRn or N + RnRn, where each Rn is independently H, alkyl, substituted C 2 -Ci 2 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
- the compound has the structure
- Rg is present or absent and when present is H, alkyl, alkenyl, alkynyl or phenyl;
- X is 0, NRn, or N + R n Rn, where each Rn is independently H, alkyl, substituted C 2 -Ci 2 alkyl, alkenyl, substituted C 4 - C 12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
- R 12 is H or alkyl, or a salt, zwitterion, or enantiomer of the compound.
- the compound has the structure
- X is 0 or NH + Rn, where Rn is H, alkyl, substituted C 2 -Ci 2 alkyl, alkenyl, substituted C 4 -C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
- R i2 is H or alkyl, or a salt, enantiomer or zwitterion of the compound.
- bond ⁇ is present. On another embodiment of the above compound, bond ⁇ is absent.
- the compound has the structure of compound 100, compound 102, compound 101, compound 103, compound 105, or compound 107; or a salt, entantiomer or zwitterions of the compound.
- the compound has the structure of compound 10OE, compound 102E, compound 101E, compound 103E, compound 105E, or compound 107E; or a salt, entantiomer or zwitterions of the compound.
- the compound has the structure
- X is NH + Rn, where Ru is present or absent and when present Ru is alkyl, substituted C 2 -C 12 alkyl, alkenyl, substituted C 4 -Ci 2 alkenyl,
- R i2 is H or alkyl, or a salt, enantiomer or zwitterion of the compound
- the compound is compound 108 or a salt enationmer or zwitterions of the compound.
- R 3 is ORio or O(CH 2 )i-6R9, where Rg is aryl or substituted ethyl; where Rio is substituted phenyl, wherein the substituent is in the para position;
- Rn is independently H, alkyl, hydroxyalkyl, substituted C 2 -C 12 alkyl, alkenyl, substituted C 4 -Ci 2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
- Ri 2 is alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H; or where R 3 is OH and R 4 is
- the compound has the structure where Ru is alkyl or hydroxylalkyl or R 4 is
- the compound when R 3 is OH, or a salt, enantiomer or zwitterion of the compound.
- the compound has the structure of compound 109, compound 110, compound 112, compound 113, or compound 114; or a salt, enantiomer or zwitterion of the compound.
- the compound has the structure of compound 109E, compound HOE, compound 112E, compound 113E or compound 114E; or a salt enatniomer or zwitterion of the compound.
- the comound 108E or compound 111 or a salt enatniomer or zwitterion of the compound.
- Certain embodiments of the disclosed compounds can contain a basic functional group, such as amino or alkylamino, and are thus capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids, or contain an acidic functional group and are thus capable of forming pharmaceutically acceptable salts with bases.
- the instant compounds therefore may be in a salt form.
- a "salt" is a salt of the instant compounds which has been modified by making acid or base salts of the compounds.
- the salt may be pharmaceutically acceptable.
- Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as phenols.
- the salts can be made using an organic or inorganic acid.
- Such acid salts are chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates, and the like.
- Phenolate salts are the alkaline earth metal salts, sodium, potassium or lithium.
- pharmaceutically acceptable salt in this respect, refers to the relatively non-toxic, inorganic and organic acid or base addition salts of compounds of the present invention.
- salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base or free acid form with a suitable organic or inorganic acid or base, and isolating the salt thus formed.
- Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.
- suitable salts see, e.g., Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19, the contents of which are hereby incorporated by reference.
- iPS cell are pluripotent stem cells which are derived from somatic cells by forced expression of genes encoding reprogramming factors, which include, for example, c-Myc, Klf4, Sox2, 0ct4 (POU5F1 ) , Iin28 and Nanog.
- reprogramming factors include, for example, c-Myc, Klf4, Sox2, 0ct4 (POU5F1 ) , Iin28 and Nanog.
- Processes for producing iPS cells have been decribed, for example, in Takahashi K and Yamanaka S., 2006; Okita K., et al, 2007; Wernig, M. et al, 2007; U.S. Patent Application Publication Nos . US 2006/0205075; US 2009/0047263; US 2009/0227032; and US 2009/0246875; the contents of each of which are hereby incorporated by reference.
- reprogramming factor are genes, such as transcription factors, which can be used for the production of iPS cells.
- Reprogramming factors include, but are not limited to, c-Myc, Klf4, Sox2, 0ct4 (POU5F1 ) , Iin28 and Nanong.
- increasing the production efficiency of iPS cells is achieved when the amount of iPS cells produced from a population of somatic cells which have been contacted with a PP2A inhibitor is greater than the amount of iPS cells which have not been contacted with a PP2A inhibitor but which have been otherwise been produced by the same process.
- the increase in production efficiency could be represented by a greater than 5%, greater than 10%, greater than 15%, greater than 20% increase in the amount of iPS cells so produced.
- alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
- Ci-C n as in “Ci-C n alkyl” is defined to include groups having 1, 2, ...., n-1 or n carbons in a linear or branched arrangement, and specifically includes methyl, ethyl, propyl, butyl, pentyl, hexyl, and so on.
- An embodiment can be C 1 -C 12 alkyl.
- Alkoxy represents an alkyl group as described above attached through an oxygen bridge.
- alkenyl refers to a non-aromatic hydrocarbon radical, straight or branched, containing at least 1 carbon to carbon double bond, and up to the maximum possible number of non- aromatic carbon-carbon double bonds may be present.
- C 2 -C n alkenyl is defined to include groups having 1, 2, ...., n-1 or n carbons.
- C2-C 6 alkenyl means an alkenyl radical having 2, 3, 4, 5, or 6 carbon atoms, and at least 1 carbon- carbon double bond, and up to, for example, 3 carbon-carbon double bonds in the case of a C$ alkenyl, respectively.
- Alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl . As described above with respect to alkyl, the straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated. An embodiment can be C 2 -Ci 2 alkenyl.
- alkynyl refers to a hydrocarbon radical straight or branched, containing at least 1 carbon to carbon triple bond, and up to the maximum possible number of non-aromatic carbon- carbon triple bonds may be present. Thus, C 2 -C n alkynyl is defined to include groups having 1, 2, ...., n-1 or n carbons.
- C 2 -C 6 alkynyl means an alkynyl radical having 2 or 3 carbon atoms, and 1 carbon-carbon triple bond, or having 4 or 5 carbon atoms, and up to 2 carbon-carbon triple bonds, or having 6 carbon atoms, and up to 3 carbon-carbon triple bonds.
- Alkynyl groups include ethynyl, propynyl and butynyl. As described above with respect to alkyl, the straight or branched portion of the alkynyl group may contain triple bonds and may be substituted if a substituted alkynyl group is indicated.
- An embodiment can be a C 2 -C n alkynyl.
- aryl is intended to mean any stable monocyclic or bicyclic carbon ring of up to 10 atoms in each ring, wherein at least one ring is aromatic.
- aryl elements include phenyl, naphthyl, tetrahydro-naphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl .
- the aryl substituent is bicyclic and one ring is non-aromatic, it is understood that attachment is via the aromatic ring.
- the substituted aryls included in this invention include substitution at any suitable position with amines, substituted amines, alkylamines, hydroxys and alkylhydroxys, wherein the "alkyl" portion of the alkylamines and alkylhydroxys is a C 2 -C n alkyl as defined hereinabove.
- the substituted amines may be substituted with alkyl, alkenyl, alkynl, or aryl groups as hereinabove defined.
- alkyl, alkenyl, alkynyl, and aryl substituents may be unsubstituted or unsubstituted, unless specifically defined otherwise.
- a (Ci-C ⁇ ) alkyl may be substituted with one or more substituents selected from OH, oxo, halogen, alkoxy, dialkylamino, or heterocyclyl, such as morpholinyl, piperidinyl, and so on.
- alkyl, alkenyl, and alkynyl groups can be further substituted by replacing one or more hydrogen atoms by non-hydrogen groups described herein to the extent possible.
- non-hydrogen groups include, but are not limited to, halo, hydroxy, mercapto, amino, carboxy, cyano and carbamoyl.
- substituted means that a given structure has a substituent which can be an alkyl, alkenyl, or aryl group as defined above.
- the term shall be deemed to include multiple degrees of substitution by a named substitutent .
- the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the
- zwitterion means a compound that is electrically neutral but carries formal positive and negative charges on different atoms. Zwitterions are polar, have high solubility in water and have poor solubility in most organic solvents.
- the compounds disclosed herein may also form zwitterions.
- a compound having the structure may also for the following zwitterionic structure
- Example 1 Inhibition of PP2A diminishes a major defense against DNA damage, cell-cycle arrest by p53 by reducing the cell concentration of p53.
- Compound 102 inhibits PP2A and PPl in lysates of human glioblastoma cell line U87 (Fig. 1) and inhibits PP2A in vivo in xenografts of U87 (subcutaneous) and in normal brain tissue of SCID mice (Fig. 2) .
- Exposure of U87MG cells in culture to compound 102 resulted in increased phosphorylated Akt (pAkt-1), PIk-I (pPlk-1), and a marked decrease in translationally controlled tumor protein (TCTP; Fig. 3) .
- TCTP is an abundant, highly conserved, multifunctional protein that binds to and stabilizes microtubules before and after mitosis and also exerts potent anti-apoptotic activity (Bommer and Thiele, 2004; Yarm, 2002; Susini et al, 2008) . Decreasing TCTP with anti-sense TCTP has been shown by others to enhance tumor reversion of v-src- transformed NIH 3T3 cells and reduction of TCTP is suggested to be the mechanism by which high concentrations of certain anti- histaminics and psychoactive drugs inhibit growth of a human lymphoma cell line (Tuynder et al, 2004) .
- pAkt-1 phosphorylation at Ser308 indicates downstream activation of the phosphatidylinositol-3-kinase (PI3K) pathway, an event generally considered to be growth-promoting (Brazil et al, 2004) .
- Akt-1 activation may be anti- or proapoptotic depending on the context of cell signaling (Andrabi et al, 2007) .
- Compound 102 inhibition of PP2A increased pAkt-1 and activated PIk-I, a regulator of a mitotic checkpoint and of the activity of TCTP.
- Compound 102 exposure also increased phosphorylated MDM2, the primary regulator of p53 activity
- pAkt-1 can directly phosphorylate
- MDM2 increasing its stability, and can phosphorylate MDMX, which binds to and further stabilizes MDM2 (Olivier et al, 2008) .
- inhibition of PP2A diminishes a major defense against DNA damage, cell-cycle arrest by p53.
- Example 2 Effects of compound 102 on decreasing p53 are maintained in the face of DNA damage by the DNA-damaging agent, Temozolomide (TMZ) .
- TMZ Temozolomide
- Example 3 Effects of PP2A inhibition by compound 102 on p53 are mimicked by another known inhibitor of PP2A, okadaic acid.
- a series of novel PP2A inhibitors, compounds 100 - 114 and compounds 100E-110E and 112E-114E have been developed.
- Compound 102 inhibits PP2A approximately 200 times as efficiently as PPl (Lu et al, 2009) .
- a consequence of inhibiting PP2A with Compound 102 is a marked reduction in the abundance of p53, even in the presence of a DNA damaging agent such as temomozolomide or doxorubicin.
- Okadaic acid a known inhibitor of PP2A at nanomolar concentrations, mimics the effects of Compound 102 on reducing p53 activity (Lu et al, 2009) .
- Compound 102 and its water soluble analog Compound 100 can be administered to animals (mice and rats) at doses which inhibit PP2A in subcutaneous xenografts of human cancers and in the normal brain tissue of these animals (Fig. 2) .
- Inhibition of PP2A after a single intraperitoneal injection achieves maximum inhibition of PP2A in tissue at 6-8 hours, after which PP2A recovers.
- Inhibition of PP2A is associated with a marked diminution of p53 in tissue, mediated apparently by marked induction of phosphorylated MDM2 (p-MDM2) .
- MDM2 is the prime regulator of p53 abundance.
- the small molecule Compound 100 and associated homologs can be used to reduce p53 activity by inhibition of PP2A providing a window of opportunity for re-programming somatic cells into iPS cells with subsequent return of p53 activity once the PP2A inhibitor is withdrawn, thereby increasing the efficiency of the process for producing iPS cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Disclosed herein are methods of inhibiting the function of p53 in a cell by contacting the cell with an effective amount of a PP2A inhibitor. Also disclosed herein are processes for producing an induced pluripotent stem (iPS) cell by contacting a somatic cell expressing at least one gene that encodes a reprogramming factor with an amount of a PP2A inhibitor effective to produce the iPS cell; reversibly inhibiting p53 function during production of an iPS cell by contacting a somatic cell with an amount of a PP2A inhibitor effective to reversibly inhibit p53 function; increasing the likelihood of producing an (iPS) cell.
Description
Methods of Modulating Cell Regulation by Inhibiting p53
This application claims priority of (i) PCT International Application No. PCT/US2009/004108 , filed July 16, 2009 and (ii) U.S. Provisional Application No. 61/269,101, filed June 18, 2009, the contents of each of which in its entirety is hereby incorporated by reference.
Throughout this application, certain publications are referenced. Full citations for these publications may be found immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to describe more fully the state-of-the art to which this invention relates.
Background of the Invention
There is an intense worldwide research effort to develop technology that reliably induces development of functional genetically intact pluripotent stem cells (iPS) from somatic cells. It has been shown that inserting as few as 3 or 4 genes into an adult mammalian cell is sufficient to convert that cell into an embryo-like state believed to be capable of developing into any tissue of the body (Science Feb 1, 2008) . A major difficulty in developing iPS cells is the inefficiency of the conversion process in which generally fewer than 1 percent of adult cells are successfully re-programmed into iPS cells.
Summary of the Invention
Provided herein is a method of inhibiting the function of p53 in a cell comprising contacting the cell with an effective amount of a PP2A inhibitor, wherein the PP2A inhibitor is a compound having the structure:
wherein bond α is present or absent;
Ri and R2 is each independently H, 0~ or OR9, where Rg is H, alkyl, substituted alkyl, alkenyl, alkynyl or aryl, or Ri and R2 together are =0;
R3 and R4 are each different, and each is OH, 0~, OR9, OR10, O(CH2)i_6R9, SH, S', SR9,
or
where X is O, S, NRn, or N+RnRi1, where each Rn is independently H, alkyl, hydroxyalkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro when R1 and R2 are =0,
-CH2CN, -CH2CO2R12, -CH2COR12, -NHR12 or -NH+ (R12) 2, where each Ri2 is independently alkyl, alkenyl or alkynyl, each of which is substituted or -unsubstituted, or H; R1O is substituted alkyl, substituted alkenyl, substituted alkynyl, or substituted aryl;
R5 and R6 is each independently H, OH, or R5 and R6 taken together are =0; and
R7 and R8 is each independently H, F, Cl, Br, SO2Ph, CO2CH3, or SR13, where R13 is H, aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl, or a salt, enantiomer or zwitterion of the compound, so as to thereby inhibit the function of p53 in the cell.
Also provided is a process for producing an induced pluripotent stem (iPS) cell comprising contacting a somatic cell expressing at least one gene that encodes a reprogramming factor with an amount of a PP2A inhibitor effective to produce the iPS cell.
Further provided is a process for reversibly inhibiting p53 function during production of an induced pluripotent stem (iPS) cell from a somatic cell expressing at least one gene that encodes a reprogramming factor comprising contacting the somatic cell with an amount of a PP2A inhibitor effective to reversibly inhibit p53 function.
Disclosed herein is also a process for increasing the likelihood of producing an induced pluripotent stem (iPS) cell comprising contacting a somatic cell expressing at least one gene that encodes a reprogramming factor with an amount of a PP2A inhibitor effective to increase the likelihood of producing an iPS.
Disclosed herein is also a process for increasing the production efficiency of induced pluripotent stem (iPS) cells, wherein the process for production of the iPS cells comprises transforming a population of somatic cells with at least one gene that encodes a reprogramming factor, the process comprising contacting the population of somatic cells with an amount of a PP2A inhibitor effective to increase the efficiency of the production of iPS cells.
Disclosed herein is also a process of producing an induced pluripotent stem cell (iPS) comprising transforming a somatic cell to express at least one gene that encodes a reprogramming factor such that the somatic becomes an iPS, wherein the improvement comprises contacting the somatic cell with an amount of a PP2A inhibitor effective to transiently reduce the function of p53 in the cell.
Brief Description of the Figures
Figure 1 : Inhibition Of PP2A and PPl Activition
Inhibition of PP2A and PPl activity in lysates of human glioblastoma cell line U87 by Compound 102 (mean and s.d.; n=3) (Ser/thr Phosphatase Assay Kit 1, Milliport, Billerica, MA) .
Figure 2: Inhibition Of PP2A Activity In U87 Subcutaneous (sc) Xenografts and In Normal Brain Tissue.
Inhibition of PP2A activity in U87 subcutaneous (sc) xenografts is shown in the left column and in normal brain issues in the right column of SCID mice at different times after i.p. injection of 1.5 mg/kg compound 102 (one mouse per point; mean of 3 lysates;
1 s.d. ) .
Figure 3: Cellular and Molecular Changes in U87 Cells Induced By Compound 102.
Cellular and molecular changes in U87 cells induced by compound 102. Western blot of U87 lysates: pAkt- 1, total Akt-1, and β-actin (left panel) and TCTP, pPlk (Tre-210), total PIk, and β-actin (right panel), after 24 hour exposure to 2.5uM compound 102.
Figure 4: p53, pMDM2 and β-actin After Exposure To Compound 102.
P53(ser-15), pMDM2 (ser-166) , and β-actin after 24 hour exposure to 2.5 uM compound 102.
Figure 5: Western Blots of p-Akt-1, p53, pMDM2 and β-actin In Lysates of U87 Cells.
Western blots of p-Akt-1, p53, pMDM2, and beta actin in lysates of U87 cells 24 hours after exposure to compound 102 at 2.5uM, Temozolomide (TMZ) at 25uM, and compound 102 plus TMZ.
Figure 6: Western Blots of p-Akt-1, p53, and β-actin In Lysates of U373 Cells.
Western blots of p-Akt-1, p53, and beta actin in lysates of U373 cells 24 hours after exposure to okadaic acid (2nM) , TMZ at 25uM, and to both drugs at the same concentrations.
Detailed Description of the Invention
The invention provides a method of inhibiting the function of p53 in a cell comprising contacting the cell with an effective amount of a PP2A inhibitor, wherein the PP2A inhibitor is a compound having the structure:
wherein bond α is present or absent;
Ri and R2 is each independently H, 0~ or ORg, where R9 is H, alkyl, substituted alkyl, alkenyl, alkynyl or aryl, or Ri and R2 together are =0;
R3 and R4 are each different, and each is OH, 0", OR9, ORi0,
O(CH2)i-6R9, SH, S", SR9,
where X is 0, S, NRU/ or N+RnRn, where each Rn is independently H, alkyl, hydroxyalkyl, substituted C2-Ci2 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro when Ri and R2 are =0,
-CH2CN, -CH2CO2Ri2, -CH2CORi2, -NHRi2 or -NH+(R^)2, where each Ri2 is independently alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H;
Rio is substituted alkyl, substituted alkenyl, substituted alkynyl, or substituted aryl; R5 and Re is each independently H, OH, or Rs and R6 taken together are =0; and R7 and R8 is each independently H, F, Cl, Br, SO2Ph, CO2CH3, or SRi3, where R13 is H, aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl, or a salt, enantiomer or zwitterion of the compound, so as to thereby inhibit the function of p53 in the cell.
In one embodiment of the above method, the compound has the structure
In another embodiment of the above method, the compound has the structure
In a further emdoiment of the above method, R4 is
where X is 0 , NRn , N+R1 IRn
where each Rn is independently H, alkyl, substituted C2-Ci2 alkyl, alkenyl, substituted C4- Ci2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro when R1 and R2 are =0,
-CH2CN, -CH2CO2Ri2, -CH2CORi2, -NHR12 or -NH+ (R12) 2, where Ri2 is H or alkyl, or a salt, enantiomer or zwitterion of the compound.
In a further embodiment, the compound is compound 104, compound 104E, compound 106, or compound 106E; or a salt, enantiomer or zwitterion of the compound.
In another embodiment of the above method, the compound has the structure
wherein bond α is present or absent; Rg is present or absent and when present is H, Ci-C10 alkyl, C2-C10 alkenyl or phenyl; and X is 0, S, NR11 or N+R11Rn, where each R11 is independently H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CO2Ri2, -CH2CORi2, -CH2CN, or -CH2CH2Ri6, where R12 is H or alkyl, and where Ri6 is any substituent that is a precursor to an aziridinyl intermediate, or a salt, zwitterion or enantiomer of the compound.
In one embodiment of the above method, the compound has the structure
wherein, bond a. is present or absent;
X is O, S, NRn or N+RnRn, where each Rn is independently H, alkyl, substituted C2-Ci2 alkyl, alkenyl, substituted Cj-Ci2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CO2Ri2, -CH2CORi2, -CH2CN, or -CH2CH2Ri6, where R12 is H or alkyl, and where R16 is any substitutent that is a aziridinyl intermediate, or a salt, zwitterion or enantiomer of a compound.
In another embodiment of the above method, the compound has the structure
Rg is present or absent and when present is H, alkyl, alkenyl, alkynyl or phenyl; and
X is 0, NRn, or N+RnRi1, where each Rn is independently H, alkyl, substituted C2-Ci2 alkyl, alkenyl, substituted C4- Ci2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CN, -CH2CO2Ri2, or -CH2CORi2, where R12 is H or alkyl, or a salt, zwitterion, or enantiomer of the compound.
In another embodiment, the compound has the structure
X is 0 or NH+Rn, where Rn is H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CN, -CH2CO2R12, or -CH2CORi2, where Ri2 is H or alkyl, or a salt, enantiomer or zwitterion of the compound.
In one embodiment of the above compound, bond α is present. On another embodiment of the above compound, bond a is absent. In a further embodiment, the compound has the structure of compound 100, compound 102, compound 101, compound 103, compound 105, or compound 107; or a salt, entantiomer or zwitterions of the compound. In another embodiment, the compound has the structure of compound 10OE, compound 102E, compound 101E, compound 103E, compound 105E, or compound 107E; or a salt, entantiomer or zwitterions of the compound.
In a further embodiment of the above method, the compound has the structure
wherein bond α is present or absent; X is NH+Rn,
where Rn is present or absent and when present Rn is al kyl , substituted C2-Ci2 al kyl , al kenyl , substituted C4-Ci2 al kenyl ,
-CH2CN , -CH2CO2Ri2 , or -CH2CORi2, where R12 is H or alkyl, or a salt, enantiomer or zwitterion of the compound
In a further embodiment of the above method, the compound is compound 108 or a salt enationmer or zwitterions of the compound.
In one embodiment of the above method,
R3 is ORio or 0 (CH2) i-6R9, where R9 is aryl or substituted ethyl; where Ri0 is substituted phenyl, wherein the substituent is in the para position;
R4 is
where X is 0, S, NRn, or N+RnRn, where each Rn is independently H, alkyl, hydroxyalkyl, substituted C2-Ci2 alkyl, alkenyl,
substituted C4-Ci2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CN, -CH2CO2Ri2, -CH2CORi2, -NHRi2 or -NH+ (Ri2) 2, where Ri2 is alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H; or where R3 is OH and R4 is
In a further embodiment of the above method, the compound has the structure
where Rn is alkyl or hydroxylalkyl or R4 is
when R3 is OH, or a salt, enantiomer or zwitterion of the compound,
In another embodiment of the above method, the compound has the structure of compound 109, compound 110, compound 112, compound 113, or compound 114; or a salt, enantiomer or zwitterion of the compound. In a further embodiment of the above method, the compound has the structure of compound 109E, compound HOE, compound 112E, compound 113E or compound 114E; or a salt enatniomer or zwitterion of the compound.
In a further embodiment, the comound 108E or compound 111; or a salt enatniomer or zwitterion of the compound.
This invention further provides a process for producing an induced pluripotent stem (iPS) cell comprising contacting a somatic cell expressing at least one gene that encodes a reprogramming factor with an amount of a PP2A inhibitor effective to produce the iPS cell.
Also provided is a process for reversibly inhibiting p53 function during production of an induced pluripotent stem (iPS) cell from a somatic cell expressing at least one gene that encodes a reprogramming factor comprising contacting the somatic cell with an amount of a PP2A inhibitor effective to reversibly inhibit p53 function.
This invention further provides a process for increasing the likelihood of producing an induced pluripotent stem (iPS) cell comprising contacting a somatic cell expressing at least one gene that encodes a reprogramming factor with an amount of a PP2A inhibitor effective increa the likelihood of producing an iPS.
This invention also provides a process for increasing the production efficiency of induced pluripotent stem (iPS) cells,
wherein the process for production of the iPS cells comprises transforming a population of somatic cells with at least one gene that encodes a reprogramming factor, the process comprising contacting the population of somatic cells with an amount of a PP2A inhibitor effective to increase the efficiency of the production of iPS cells.
This invention further provides a process of producing an induced pluripotent stem cell (iPS) comprising transforming a somatic cell to express at least one gene that encodes a reprogramming factor such that the somatic becomes an iPS, wherein the improvement comprises contacting the somatic cell with an amount of a PP2A inhibitor effective to transiently reduce the function of p53 in the cell.
In one embodiment of any of the above processes, the PP2A inhibitor is a compound having the structure:
wherein bond α is present or absent;
Ri and R2 is each independently H, O~ or ORg, where Rg is H, alkyl, substituted alkyl, alkenyl, alkynyl or aryl, or Ri and R2 together are =0;
where X is 0, S, NRn, or N+RnRn, where each Rn is independently H, alkyl, hydroxyalkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-Ci2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro when Ri and R2 are =0,
-CH2CN, -CH2CO2Ri2, -CH2CORi2, -NHR12 or -NH+(Ri2)2, where each Ri2 is independently alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H; Rio is substituted alkyl, substituted alkenyl, substituted alkynyl, or substituted aryl; and Rξ, is each independently H, OH, or R5 and Re taken together are =0; and
R7 and R8 is each independently H, F, Cl, Br, SO2Ph, CO2CH3, or SRi3, where R13 is H, aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl, or a salt, enantiomer or zwitterion of the compound.
In one embodiment of the above processes, the compound has the structure
In a further embodiment of the above processes, the compound has the structure
where X is 0 , NRn , N+RnRiI
where each Ri1 is independently H, alkyl, substituted C2-Ci2 alkyl, alkenyl, substituted C4- Ci2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro when Ri and R2 are =0,
-CH2CN , -CH2CO2Ri2 , -CH2CORi2 , -NHRi2 or -NH+ ( R12 ) 2 , whe re Ri2 i s H or al kyl .
In another embodiment of the above processes, the compound is In a further embodiment, the compound is compound 104, compound 104E, compound 106, or compound 106E; or a salt, enantiomer or zwitterion of the compound.
In another embodiment of the above processes, the compound has the structure
wherein bond α is present or absent; R9 is present or absent and when present is H, Ci-Cio alkyl, C2-CiO alkenyl or phenyl; and X is 0, S, NRn or N+RnRn, where each Rn is independently H, alkyl, substituted C2-Ci2 alkyl, alkenyl, substituted C4-Ci2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CO2Ri2, -CH2CORi2, -CH2CN, or -CH2CH2Ri6, where Ri2 is H or alkyl, and where Ri6 is any substituent that is a precursor to an aziridinyl intermediate, or a salt, zwitterion or enantiomer of the compound.
In one embodiment of the above processes, the compound has the structure
wherein, bond α is present or absent;
X is 0, S, NRn or N+RnRn, where each Rn is independently H, alkyl, substituted C2-Ci2 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CO2Ri2, -CH2CORi2, -CH2CN, or -CH2CH2Ri6, where Ri2 is H or alkyl, and where R16 is any substitutent that is a aziridinyl intermediate, or a salt, zwitterion or enantiomer of a compound.
In another embodiment of the above processes, the compound has the structure
Rg is present or absent and when present is H, alkyl, alkenyl, alkynyl or phenyl; and
X is 0, NRn, or N+RnRn, where each Rn is independently H, alkyl, substituted C2-Ci2 alkyl, alkenyl, substituted C4- C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CN, -CH2CO2Ri2, or -CH2CORi2, where R12 is H or alkyl, or a salt, zwitterion, or enantiomer of the compound.
In another embodiment, the compound has the structure
X is 0 or NH+Rn, where Rn is H, alkyl, substituted C2-Ci2 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CN, -CH2CO2Ri2, or -CH2CORi2, where Ri2 is H or alkyl, or a salt, enantiomer or zwitterion of the compound.
In one embodiment of the above compound, bond α is present. On another embodiment of the above compound, bond α is absent. In a further embodiment, the compound has the structure of compound 100, compound 102, compound 101, compound 103, compound 105, or compound 107; or a salt, entantiomer or zwitterions of the compound. In another embodiment, the compound has the structure of compound 10OE, compound 102E, compound 101E, compound 103E, compound 105E, or compound 107E; or a salt, entantiomer or zwitterions of the compound.
In a further embodiment of the above processes, the compound has the structure
wherein bond α is present or absent; X is NH+Rn,
where Ru is present or absent and when present Ru is alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-Ci2 alkenyl,
-CH2CN, -CH2CO2R12, or -CH2CORi2, where Ri2 is H or alkyl, or a salt, enantiomer or zwitterion of the compound
In a further embodiment of the above processes, the compound is compound 108 or a salt enationmer or zwitterions of the compound.
In one embodiment of the above processes,
R3 is ORio or O(CH2)i-6R9, where Rg is aryl or substituted ethyl; where Rio is substituted phenyl, wherein the substituent is in the para position;
R4 is
where X is O, S, NRn, or N+RnRn, where each Rn is independently H, alkyl, hydroxyalkyl, substituted C2-C12 alkyl, alkenyl,
substituted C4-Ci2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CN, -CH2CO2Ri2, -CH2CORi2, -NHRi2 or -NH+ (R12) 2, where Ri2 is alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H; or where R3 is OH and R4 is
In a further embodiment of the above processes, the compound has the structure
where Ru is alkyl or hydroxylalkyl or R4 is
when R3 is OH, or a salt, enantiomer or zwitterion of the compound.
In another embodiment of the above processes, the compound has the structure of compound 109, compound 110, compound 112, compound 113, or compound 114; or a salt, enantiomer or zwitterion of the compound. In a further embodiment of the above processes, the compound has the structure of compound 109E, compound HOE, compound 112E, compound 113E or compound 114E; or a salt enatniomer or zwitterion of the compound.
In a further embodiment, the comound 108E or compound 111; or a salt enatniomer or zwitterion of the compound.
Definitions
Certain embodiments of the disclosed compounds can contain a basic functional group, such as amino or alkylamino, and are thus capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids, or contain an acidic functional group and are thus capable of forming pharmaceutically acceptable salts with bases. The instant compounds therefore may be in a salt form. As used herein, a "salt" is a salt of the instant compounds which has been modified by making acid or base salts of the compounds. The salt may be pharmaceutically acceptable. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as phenols. The salts can be made using an organic or inorganic acid. Such acid salts are chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates, and the like. Phenolate salts are the alkaline earth metal salts, sodium, potassium or lithium. The term "pharmaceutically acceptable salt" in this respect, refers to the relatively non-toxic, inorganic and organic acid or base addition salts of compounds of the present invention. These
salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base or free acid form with a suitable organic or inorganic acid or base, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. For a description of possible salts, see, e.g., Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19, the contents of which are hereby incorporated by reference.
As used herein, "induced pluripotent stem (iPS) cell" are pluripotent stem cells which are derived from somatic cells by forced expression of genes encoding reprogramming factors, which include, for example, c-Myc, Klf4, Sox2, 0ct4 (POU5F1 ) , Iin28 and Nanog. Processes for producing iPS cells have been decribed, for example, in Takahashi K and Yamanaka S., 2006; Okita K., et al, 2007; Wernig, M. et al, 2007; U.S. Patent Application Publication Nos . US 2006/0205075; US 2009/0047263; US 2009/0227032; and US 2009/0246875; the contents of each of which are hereby incorporated by reference.
As used herein, "reprogramming factor" are genes, such as transcription factors, which can be used for the production of iPS cells. Reprogramming factors include, but are not limited to, c-Myc, Klf4, Sox2, 0ct4 (POU5F1 ) , Iin28 and Nanong.
As used herein, increasing the production efficiency of iPS cells is achieved when the amount of iPS cells produced from a
population of somatic cells which have been contacted with a PP2A inhibitor is greater than the amount of iPS cells which have not been contacted with a PP2A inhibitor but which have been otherwise been produced by the same process. For example, the increase in production efficiency could be represented by a greater than 5%, greater than 10%, greater than 15%, greater than 20% increase in the amount of iPS cells so produced.
As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Thus, Ci-Cn as in "Ci-Cn alkyl" is defined to include groups having 1, 2, ...., n-1 or n carbons in a linear or branched arrangement, and specifically includes methyl, ethyl, propyl, butyl, pentyl, hexyl, and so on. An embodiment can be C1-C12 alkyl. "Alkoxy" represents an alkyl group as described above attached through an oxygen bridge.
The term "alkenyl" refers to a non-aromatic hydrocarbon radical, straight or branched, containing at least 1 carbon to carbon double bond, and up to the maximum possible number of non- aromatic carbon-carbon double bonds may be present. Thus, C2-Cn alkenyl is defined to include groups having 1, 2, ...., n-1 or n carbons. For example, "C2-C6 alkenyl" means an alkenyl radical having 2, 3, 4, 5, or 6 carbon atoms, and at least 1 carbon- carbon double bond, and up to, for example, 3 carbon-carbon double bonds in the case of a C$ alkenyl, respectively. Alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl . As described above with respect to alkyl, the straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated. An embodiment can be C2-Ci2 alkenyl.
The term "alkynyl" refers to a hydrocarbon radical straight or branched, containing at least 1 carbon to carbon triple bond, and up to the maximum possible number of non-aromatic carbon- carbon triple bonds may be present. Thus, C2-Cn alkynyl is defined to include groups having 1, 2, ...., n-1 or n carbons. For example, "C2-C6 alkynyl" means an alkynyl radical having 2 or 3 carbon atoms, and 1 carbon-carbon triple bond, or having 4 or 5 carbon atoms, and up to 2 carbon-carbon triple bonds, or having 6 carbon atoms, and up to 3 carbon-carbon triple bonds. Alkynyl groups include ethynyl, propynyl and butynyl. As described above with respect to alkyl, the straight or branched portion of the alkynyl group may contain triple bonds and may be substituted if a substituted alkynyl group is indicated. An embodiment can be a C2-Cn alkynyl.
As used herein, "aryl" is intended to mean any stable monocyclic or bicyclic carbon ring of up to 10 atoms in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, naphthyl, tetrahydro-naphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl . In cases where the aryl substituent is bicyclic and one ring is non-aromatic, it is understood that attachment is via the aromatic ring. The substituted aryls included in this invention include substitution at any suitable position with amines, substituted amines, alkylamines, hydroxys and alkylhydroxys, wherein the "alkyl" portion of the alkylamines and alkylhydroxys is a C2-Cn alkyl as defined hereinabove. The substituted amines may be substituted with alkyl, alkenyl, alkynl, or aryl groups as hereinabove defined.
The alkyl, alkenyl, alkynyl, and aryl substituents may be unsubstituted or unsubstituted, unless specifically defined otherwise. For example, a (Ci-Cδ) alkyl may be substituted with
one or more substituents selected from OH, oxo, halogen, alkoxy, dialkylamino, or heterocyclyl, such as morpholinyl, piperidinyl, and so on.
In the compounds of the present invention, alkyl, alkenyl, and alkynyl groups can be further substituted by replacing one or more hydrogen atoms by non-hydrogen groups described herein to the extent possible. These include, but are not limited to, halo, hydroxy, mercapto, amino, carboxy, cyano and carbamoyl.
The term "substituted" as used herein means that a given structure has a substituent which can be an alkyl, alkenyl, or aryl group as defined above. The term shall be deemed to include multiple degrees of substitution by a named substitutent . Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the
(two or more) substituents can be the same or different.
As used herein, "zwitterion" means a compound that is electrically neutral but carries formal positive and negative charges on different atoms. Zwitterions are polar, have high solubility in water and have poor solubility in most organic solvents.
The compounds disclosed herein may also form zwitterions. For example, a compound having the structure
may also for the following zwitterionic structure
Compounds 100 - 114 and IOOE -HOE and 112E-114E, as described herein, were obtained from Lixte Biotechnology, Inc. 248 Route 25A, No. 2, East Setauket, New York. The structure of compounds 100-114 and 100E-110E and 112E - 114E are listed in Table 1. Processes for making these compounds can be found in PCT International Application Publication WO 2008/097561, the contents of which are hereby incorporated by reference.
Table 1 :
Experimental Details
Example 1: Inhibition of PP2A diminishes a major defense against DNA damage, cell-cycle arrest by p53 by reducing the cell concentration of p53.
Compound 102 inhibits PP2A and PPl in lysates of human glioblastoma cell line U87 (Fig. 1) and inhibits PP2A in vivo in xenografts of U87 (subcutaneous) and in normal brain tissue of SCID mice (Fig. 2) . Exposure of U87MG cells in culture to compound 102 resulted in increased phosphorylated Akt (pAkt-1), PIk-I (pPlk-1), and a marked decrease in translationally controlled tumor protein (TCTP; Fig. 3) . TCTP is an abundant, highly conserved, multifunctional protein that binds to and stabilizes microtubules before and after mitosis and also exerts potent anti-apoptotic activity (Bommer and Thiele, 2004; Yarm, 2002; Susini et al, 2008) . Decreasing TCTP with anti-sense TCTP has been shown by others to enhance tumor reversion of v-src- transformed NIH 3T3 cells and reduction of TCTP is suggested to be the mechanism by which high concentrations of certain anti- histaminics and psychoactive drugs inhibit growth of a human lymphoma cell line (Tuynder et al, 2004) .
pAkt-1 phosphorylation at Ser308 indicates downstream activation of the phosphatidylinositol-3-kinase (PI3K) pathway, an event generally considered to be growth-promoting (Brazil et al, 2004) . Akt-1 activation, however, may be anti- or proapoptotic depending on the context of cell signaling (Andrabi et al, 2007) . Compound 102 inhibition of PP2A increased pAkt-1 and activated PIk-I, a regulator of a mitotic checkpoint and of the activity of TCTP. Compound 102 exposure also increased phosphorylated MDM2, the primary regulator of p53 activity
(Vogelstein et al, 2000; Vazquez et al, 2008) and decreased the abundance of p53 (Fig. 4) . pAkt-1 can directly phosphorylate
MDM2, increasing its stability, and can phosphorylate MDMX, which binds to and further stabilizes MDM2 (Olivier et al, 2008) . Thus inhibition of PP2A diminishes a major defense against DNA damage, cell-cycle arrest by p53.
Example 2: Effects of compound 102 on decreasing p53 are maintained in the face of DNA damage by the DNA-damaging agent, Temozolomide (TMZ) .
We found that there is an increase in tumor cell killing by compound 102 plus TMZ because inhibition of PP2A renders cells more vulnerable to TMZ by inhibiting p53 mediated DNA damage arrest (Lu et al . , 2009) . The effects of compound 102, TMZ, and compound 102 plus TMZ on the amount of pAkt, p53 and MDM2 in U87MG, a cell line with wild-type p53 (Short et al, 2007) were assessed by Western blots. Exposure of U87MG cells to compound 102 alone for 24 hours increased both pAkt-1 and MDM2 and eliminated p53; TMZ alone decreased pAkt-1, increased p53, and had little effect on MDM2. Adding compound 102 prevented the decrease in pAkt-1 caused by TMZ alone and increased MDM2 in the face of continued increased expression of p53 (Fig. 5) .
Example 3: Effects of PP2A inhibition by compound 102 on p53 are mimicked by another known inhibitor of PP2A, okadaic acid.
The same molecular changes in pAkt-1 and p53 induced by compound 102, TMZ, and compound 102 plus TMZ occurred in U87 cells when Okadaic acid, at a concentration (2 nM) that is expected to inhibit PP2A and not PPl (Hart et al, 2004), was substituted for compound 102 (Fig. 6) supporting the hypothesis that the effects of compound 102 result from inhibition of PP2A.
Example 4 :
Recently, several research teams have discovered that silencing the activity of the small P53 pathway increases the success rate of re-programming. In 2009, five groups reported that inhibiting p53 activity greatly improved the efficiency of iPS generation (Hong et al, 2009; Li et al, 2009; Kawamura et al, 2009; Marion et al, 2009; Utikal et al, 2009) . These groups have used genetic and molecular techniques to reduce or eliminate p53 function and showed that this manipulation was associated with increased re-programming efficiency of human somatic cells.
Although the inhibition of p53 activity has generated considerable excitement because of the marked improvement in the generation of iPS, there is concern that elimination of p53 function, an activity which is a major defense mechanism for protecting the cell from replicating damaged DNA, could not be used for inducing iPS cells for clinical use (Krizhanovsky and Lowe, 2009) .
A series of novel PP2A inhibitors, compounds 100 - 114 and compounds 100E-110E and 112E-114E have been developed. We have shown that Compound 102 inhibits PP2A approximately 200 times as efficiently as PPl (Lu et al, 2009) . A consequence of inhibiting
PP2A with Compound 102 is a marked reduction in the abundance of p53, even in the presence of a DNA damaging agent such as temomozolomide or doxorubicin. Okadaic acid, a known inhibitor of PP2A at nanomolar concentrations, mimics the effects of Compound 102 on reducing p53 activity (Lu et al, 2009) .
Compound 102 and its water soluble analog Compound 100, can be administered to animals (mice and rats) at doses which inhibit PP2A in subcutaneous xenografts of human cancers and in the normal brain tissue of these animals (Fig. 2) . Inhibition of PP2A after a single intraperitoneal injection achieves maximum inhibition of PP2A in tissue at 6-8 hours, after which PP2A recovers. Inhibition of PP2A is associated with a marked diminution of p53 in tissue, mediated apparently by marked induction of phosphorylated MDM2 (p-MDM2) . MDM2 is the prime regulator of p53 abundance.
Thus, the small molecule Compound 100 and associated homologs, for example the compounds disclosed herein at Table 1, can be used to reduce p53 activity by inhibition of PP2A providing a window of opportunity for re-programming somatic cells into iPS cells with subsequent return of p53 activity once the PP2A inhibitor is withdrawn, thereby increasing the efficiency of the process for producing iPS cells.
References
1. News Focus (2008) "A Seismic Shift For Stem Cell Research", Science, 319:560-563.
2. Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19
3. Bommer, UA, and Thiele, BJ (2004), "The translationally controlled tumor protein (TCTP, ." International Journal of Biochemistry & Cell Biology, VoI .36 pp. 379-385.
4. Brazil, D. P., Yang, Z. -Z. & Hemmings, B. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends in Biochemical Sciences 29, 233-242 (2004) .
5. Hart, M. E., Chamberlin, A. A., Walkom, C, Sakoff, J. A. & McCluskey, A. Modified nor-cantharidins : synthesis, protein phosphatases 1 and 2A inhibition, and anti-cancer activity. Bioorg. Med. Chem. Letters. 14, 1969-1973 (2004) .
6. Hong et al . (2009) "Suppression Of Induced Pluripotent Stem Cell Generation By The p53-p21 Pathwway", Nature, 460:1132- 1135.
7. Kawamura, T. et al. (2009) "Linking The p53 Tumour Suppressor Pathway To Somatic Cell Reporgramming", Nature 460:1140-1144.
8. Krizhanovsky, K. and Lowe, S. W. (2009) "The Promises And Perils Of p53", Nature 460:1085-1086.
9. Li, H. et al. (2009) "The Ink4/Arf Locus Is A Barrier for iPS Cell Reprogramming" Nature 460(1136-1139) .
10. Lu, J. et al. (2009) "Inhibiting Of Serine/Threonine Phosphatase PP2A enhances Cancer Chemotherapy By Blocking DNA Damage Induced Defense Mechanisms", PNAS,
106(28) =11697-11702.
11. Marion, R. M. et al. (2009) "A p53-Mediated DNA Damage Response Limits Reprogramming To Ensure iPS Cell Genomic Integrity", Nature 460:1149-1153.
12. Okita, K et al. (2007) "Generation Of Germline-Competent Induced Pluripotent Stem Cells", Nature 448 (7151 ) : 260-262.
13. Olivier, M. et al. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Therapy 19 Sept 2008; doi: 10.1038/cgt .2008.69, pages 1-12 (2008) .
14. Short, S. C. et al. DNA repair after irradiation in glioma cells and normal human astrocytes. Neuro-Oncology 9, 404- 411 (2007) .
15. Susini, L et al. (2008) . "TCTP protects from apoptotic cell death by antagonizing bax function." Cell Death and Differentiation, 15 Feb. 2008 : DOI : 10.1038/cdd.2008.18.
16. Takahashi, K and Yamanaka, S. (2006) "Induction Of Pluripotent Stem Cells From Mouse Embryonic And Adult Fibroblast Cultures By Defined Factors", Cell, 126(4) : 652- 655.
17. Utikal, J. et al. (2009) "Immortalization eliminates A Roadblock During Cellular Reprogramming Into iPS Cells", Nature, 460: 1145-1148.
18. Vazquez, A., Bond, E E, Levine, A. J. & Bond, G. L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nature Rev. Cancer 7, 979-987 (2008) .
19. Vogelstein, B., Lane D. & Levine, A. J. Surfing the p53 network. Nature 408,307-310 (2000) .
20. Wernig, M. (2007) "In Vitro Reprogramming Of Fibroblasts into a pluripotent ES-Cell-Like State", Nature
448 (7151) :318-324.
21. Yarm, FR, (2002) . "PIk Phosphorylation Regulates the Microtubule-Stabilizing Protein TCTP." Molecular and Cellular Biology, Vol. 22, pp. 6209-6621.
22. Tuynder, M. et al. (2004) . "Translationally controlled tumor protein is a target of tumor reversion." PNAS, Vol.101, pp. 15364-15369.
23. U.S. Patent Application Publication NO. 2006/0205075 published September 14, 2006.
24. U.S. Patent Application Publication No. 2009/0047263, published February 19, 2009.
25. U.S. Patent Application Publication No. 2009/0227032 published September 10, 2009.
26. U.S. Patent Application Publication No. 2009/0246875 published October 1, 2009.
Claims
1. A method of inhibiting the function of p53 in a cell comprising contacting the cell with an effective amount of a PP2A inhibitor, wherein the PP2A inhibitor is a compound having the structure:
wherein
bond α is present or absent;
Ri and R2 is each independently H, 0" or OR9, where Rg is H, alkyl, substituted alkyl, alkenyl, alkynyl or aryl, or Ri and R2 together are =0;
R3 and R4 are each different, and each is OH, 0", ORg, OR10,
0 (CH2) i-6Rg, SH, S", SR9,
where X is 0, S, NRn, or N+RnRn, where each R11 is independently H, alkyl, hydroxyalkyl, substituted C2-Ci2 alkyl, alkenyl, substituted C4-Ci2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro when Ri and R2 are =0,
-CH2CN, -CH2CO2Ri2, -CH2CORi2, -NHRi2 or -NH+(R^)2, where each Ri2 is independently alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H;
Rio is substituted alkyl, substituted alkenyl, substituted alkynyl, or substituted aryl;
R5 and Rs is each independently H, OH, or R5 and Rε taken together are =0; and
R7 and R8 is each independently H, F, Cl, Br, SO2Ph, CO2CH3, or SRi3, where R13 is H, aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl,
or a salt, enantiomer or zwitterion of the compound, so as to thereby inhibit the function of p53 in the cell.
2. The method of claim 1, wherein the compound has the structure
3. The method of claim 2, wherein the compound has the structure
4. The method of claim 1, wherein R4 is
H
A' /CH3
"CH3 where X is 0 , NRn, N+RnRn where each Rn is independently H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4- C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro when Ri and R2 are =0,
-CH2CN, -CH2CO2Ri2, -CH2CORi2, -NHR22 or -NH+ (Ri2) 2, where Ri2 is H or alkyl, or a salt, enantiomer or zwitterion of the compound.
5. The method of claim 4, wherein the compound is
6. The method of claim 1, wherein the compound has the structure
wherein bond a. is present or absent; Rg is present or absent and when present is H, Ci-Cio alkyl, C2-C10 alkenyl or phenyl; and X is 0, S, NRn or N+RnRu, where each Rn is independently H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-Ci2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CO2Ri2, -CH2CORi2, -CH2CN, or -CH2CH2Ri6, where Ri2 is H or alkyl, and where R16 is any substituent that is a precursor to an aziridinyl intermediate, or a salt, zwitterion or enantiomer of the compound.
7. The method of claim 6, wherein the compound has the structure
wherein,
bond α is present or absent; X is O, S, NRn or N+RnRn, where each Rn is independently H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CO2R12, -CH2CORi2, -CH2CN, or -CH2CH2Ri6, where R12 is H or alkyl, and where R16 is any substitutent that is a aziridinyl intermediate, or a salt, zwitterion or enantiomer of a compound.
8. The method of claim 1, wherein the compound has the structure
wherein bond α is present or absent;
Rg is present or absent and when present is H, alkyl, alkenyl, alkynyl or phenyl; and
X is 0, NRn, or N+RnRn, where each Rn is independently H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4- C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CN , -CH2CO2Ri2 , or -CH2CORi2, where R12 i s H or a l kyl ,
or a salt, zwitterion, or enantiomer of the compound.
9. The method of claim 8, wherein the compound has the structure •
X is 0 or NH+Rn, where Ru is H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
10. The method of claim 8, wherein bond α is present.
11. The method of claim 8, wherein bond α is absent.
12. The method of claim 11, wherein the compound has the structure :
13. The method of claim 10, wherein the compound has the structure
14. The method of claim wherein the compound has the structure
wherein bond α is present or absent; X is NH+Ri1, where Rn is present or absent and when present Rn is alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl,
-CH2CN, -CH2CO2Ri2, or -CH2CORi2, where R12 is H or alkyl, or a salt, enantiomer or zwitterion of the compound
15. The method of claim 1, wherein the compound has the structure
16. The method method of claim 1, wherein R3 is ORio or 0 (CH2) 1-6R9, where Rg is aryl or substituted ethyl; where Rio is substituted phenyl, wherein the substituent is in the para position;
R4 is
where X is 0, S, NRn, or N+RnRn, where each Rn is independently H, alkyl, hydroxyalkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-Ci2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CN, -CH2CO2Ri2, -CH2CORi2, -NHRi2 or -NH+ (Ri2) 2, where Ri2 is alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H;
enantiomer or zwitterion of the compound.
17. The method of claim 16, wherein the compound has the structure where Rn is al kyl or hydroxylalkyl or R4 is
18. The method of claim 17, wherein the compound has the structure
19. A process for producing an induced pluripotent stem (iPS) cell comprising contacting a somatic cell expressing at least one gene that encodes a reprogramming factor with an amount of a PP2A inhibitor effective to produce the iPS cell.
20. A process for reversibly inhibiting p53 function during production of an induced pluripotent stem (iPS) cell from a somatic cell expressing at least one gene that encodes a reprogramming factor comprising contacting the somatic cell with an amount of a PP2A inhibitor effective to reversibly inhibit p53 function.
21. A process for increasing the likelihood of producing an induced pluripotent stem (iPS) cell comprising contacting a somatic cell expressing at least one gene that encodes a reprogramming factor with an amount of a PP2A inhibitor effective increa the likelihood of producing an iPS.
22. A process for increasing the production efficiency of induced pluripotent stem (iPS) cells, wherein the process for production of the iPS cells comprises transforming a population of somatic cells with at least one gene that encodes a reprogramming factor, the process comprising contacting the population of somatic cells with an amount of a PP2A inhibitor effective to increase the efficiency of the production of iPS cells.
23. A process of producing an induced pluripotent stem cell
(iPS) comprising transforming a somatic cell to express at least one gene that encodes a reprogramming factor such that the somatic becomes an iPS, wherein the improvement comprises contacting the somatic cell with an amount of a PP2A inhibitor effective to transiently reduce the function of p53 in the cell.
24. The process of any of claim 19-23, wherein the PP2A inhibitor is a compound having the structure:
wherein
bond α is present or absent;
Ri and R2 is each independently H, 0" or ORg, where Rg is H, alkyl, substituted alkyl, alkenyl, alkynyl or aryl, or Ri and R2 together are =0;
R3 and R4 are each different, and each is OH, 0", ORg, ORio,
0 (CH2) i-6R9, SH, S", SR9,
where X is O, S, NRn, OrN+RnRn, where each Rn is independently H, alkyl, hydroxyalkyl , substituted C2-Ci2 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro when Ri and R2 are =0,
-CH2CN, -CH2CO2Ri2 , -CH2CORi2, -NHRi2 or -NH+ (Ri2 J 2, where each Ri2 is independently alkyl , alkenyl or alkynyl , each of which is substituted or unsubstituted, or H; Rio is substituted alkyl, substituted alkenyl, substituted alkynyl, or substituted aryl;
R5 and Re is each independently H, OH, or R5 and R6 taken together are =0; and
R7 and Rs is each independently H, F, Cl, Br, SO2PI1, CO2CH3, or SRi3, where Ri3 is H, aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl,
or a salt, enantiomer or zwitterion of the compound.
25. The process of claim 24, wherein the compound has the structure
26. The process of claim 25, wherein the compound has the structure
27 . The process of claim 24 , wherein R4 is where X is 0 , NRn, N+RnRu where each Rn is independently H, alkyl, substituted C2-Ci2 alkyl, alkenyl, substituted C4- Ci2 alkenyl, alkynyl, substituted alkynyl, aryl , substituted aryl where the substituent is other than chloro when R1 and R2 are =0,
-CH2CN, -CH2CO2Ri2, -CH2CORi2, -NHRi2 or -NH+(Ri2J2, where Ri2 is H or alkyl .
28. The process of claim 27, wherein the compound is
29. The process of claim 24, wherein the compound has the structure
wherein bond α is present or absent; Rg is present or absent and when present is H, Ci-Cio alkyl, C2-C10 alkenyl or phenyl; and X is 0, S, NR11 or N+R11Ri1, where each R11 is independently H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CO2Ri2, -CH2CORi2, -CH2CN, or -CH2CH2Ri6, where Ri2 is H or alkyl, and where Riβ is any substituent that is a precursor to an aziridinyl intermediate, or a salt, zwitterion or enantiomer of the compound.
30. The process of claim 29, wherein the compound has the structure
wherein,
bond α is present or absent;
X is O, S, NRn or N+RnRn, where each Ru is independently H, alkyl, substituted C2-Ci2 alkyl, alkenyl, substituted C4-Ci2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CO2Ri2, -CH2CORi2, -CH2CN, or -CH2CH2Ri6, where R12 is H or alkyl , and where Riβ is any substitutent that is a aziridinyl intermediate, or a salt, zwitterion or enantiomer of a compound.
31. The process of claim 24, wherein the compound has the structure
wherein bond α is present or absent;
Rg is present or absent and when present is H, alkyl, alkenyl, alkynyl or phenyl; and
X is 0, NRu, or N+RnRn, where each Rn is independently H, alkyl, substituted C2-Ci2 alkyl, alkenyl, substituted C4- Ci2 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
or a salt, zwitterion, or enantiomer of the compound.
32. The process of claim 31, wherein the compound has the structure
X is 0 or NH+Rn, where Rn is H, alkyl, substituted C2-Ci2 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CN, -CH2CO2Ri2, or -CH2CORi2, where Ri2 is H or alkyl .
33. The process of claim 31, wherein bond α is present
34. The process of claim 31, wherein bond α is absent. - Sl -
35. The process of claim 34, wherein the compound has the structure:
36. The process of claim 33, wherein the compound has the structure
37. The process of claim 31, wherein the compound has the structure
wherein bond α is present or absent; X is NH+R11, where R11 is present or absent and when present R11 is alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl,
-CH2CN, -CH2CO2R12, or -CH2COR12, where R12 is H or alkyl .
38. The process of claim 24, wherein the compound has the structure
39. The method process of claim 24, wherein R3 is ORio or 0 (CH2) 1-6R9, where R9 is aryl or substituted ethyl; where Rio is substituted phenyl, wherein the substituent is in the para position;
R4 is
where X is O, S, NRn, or N+RnRn, where each Rn is independently H, alkyl, hydroxyalkyl , substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
-CH2CN, -CH2CO2Ri2, -CH2CORi2, -NHRi2 or -NH+(Ri2J2, where Ri2 is alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H;
40. The process of claim 39, wherein the compound has the structure where Rn is alkyl or hydroxylalkyl or R4 is
41. The method of claim 40, wherein the compound has the structure
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/378,623 US20120135522A1 (en) | 2009-06-18 | 2010-02-01 | Methods of modulating cell regulation by inhibiting p53 |
US13/870,763 US9526915B2 (en) | 2008-08-01 | 2013-04-25 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
US15/385,357 US20170259081A1 (en) | 2008-08-01 | 2016-12-20 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26910109P | 2009-06-18 | 2009-06-18 | |
US61/269,101 | 2009-06-18 | ||
PCT/US2009/004108 WO2010014141A1 (en) | 2008-08-01 | 2009-07-16 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
USPCT/US2009/004108 | 2009-07-16 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/004108 Continuation WO2010014141A1 (en) | 2008-08-01 | 2009-07-16 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
PCT/US2009/004108 Continuation-In-Part WO2010014141A1 (en) | 2008-08-01 | 2009-07-16 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/378,623 A-371-Of-International US20120135522A1 (en) | 2009-06-18 | 2010-02-01 | Methods of modulating cell regulation by inhibiting p53 |
US13/870,763 Continuation US9526915B2 (en) | 2008-08-01 | 2013-04-25 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010147612A1 true WO2010147612A1 (en) | 2010-12-23 |
Family
ID=43356659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/000279 WO2010147612A1 (en) | 2008-08-01 | 2010-02-01 | Methods of modulating cell regulation by inhibiting p53 |
Country Status (2)
Country | Link |
---|---|
US (2) | US9526915B2 (en) |
WO (1) | WO2010147612A1 (en) |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102533828A (en) * | 2011-12-23 | 2012-07-04 | 苏州大学附属第一医院 | Recombinant plasmid and virus of tissue specificity and application thereof. |
WO2013058403A1 (en) | 2011-10-21 | 2013-04-25 | 国立大学法人京都大学 | Method for culturing pluripotency-maintained singly dispersed cells by means of laminar flow |
WO2013077423A1 (en) | 2011-11-25 | 2013-05-30 | 国立大学法人京都大学 | Method for culturing pluripotent stem cell |
US8455688B2 (en) | 2007-10-01 | 2013-06-04 | Lixte Biotechnology, Inc. | HDAC inhibitors |
US8541458B2 (en) | 2008-08-01 | 2013-09-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
WO2014123242A1 (en) | 2013-02-08 | 2014-08-14 | 国立大学法人京都大学 | Production methods for megakaryocytes and platelets |
WO2014136581A1 (en) | 2013-03-06 | 2014-09-12 | 国立大学法人京都大学 | Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells |
WO2014148646A1 (en) | 2013-03-21 | 2014-09-25 | 国立大学法人京都大学 | Pluripotent stem cell for neuronal differentiation induction |
WO2014157257A1 (en) | 2013-03-25 | 2014-10-02 | 公益財団法人先端医療振興財団 | Cell sorting method |
WO2014168941A1 (en) | 2013-04-09 | 2014-10-16 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
WO2014168264A1 (en) | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | Method for inducing alveolar epithelium progenitor cells |
WO2014185358A1 (en) | 2013-05-14 | 2014-11-20 | 国立大学法人京都大学 | Efficient myocardial cell induction method |
WO2014192909A1 (en) | 2013-05-31 | 2014-12-04 | iHeart Japan株式会社 | Layered cell sheet incorporating hydrogel |
WO2014200115A1 (en) | 2013-06-11 | 2014-12-18 | 国立大学法人京都大学 | Method for producing renal precursor cells, and drug containing renal precursor cells |
WO2015020113A1 (en) | 2013-08-07 | 2015-02-12 | 国立大学法人京都大学 | Method for producing pancreatic hormone-producing cell |
WO2015034012A1 (en) | 2013-09-05 | 2015-03-12 | 国立大学法人京都大学 | New method for inducing dopamine-producing neural precursor cells |
WO2015064754A1 (en) | 2013-11-01 | 2015-05-07 | 国立大学法人京都大学 | Novel chondrocyte induction method |
US9079917B2 (en) | 2007-02-06 | 2015-07-14 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
EP3081638A1 (en) | 2015-04-16 | 2016-10-19 | Kyoto University | Method for producing pseudo-islets |
US9526915B2 (en) | 2008-08-01 | 2016-12-27 | John S. Kovach | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
WO2017183736A1 (en) | 2016-04-22 | 2017-10-26 | 国立大学法人京都大学 | Method for producing dopamine-producing neural precursor cells |
US9833450B2 (en) | 2015-02-19 | 2017-12-05 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders |
EP3305899A1 (en) | 2011-07-25 | 2018-04-11 | Kyoto University | Method for screening induced pluripotent stem cells |
US9988394B2 (en) | 2015-05-15 | 2018-06-05 | Lixte Biotechnology Inc. | Oxabicycloheptane prodrugs |
WO2018124118A1 (en) | 2016-12-27 | 2018-07-05 | 住友化学株式会社 | Evaluation method and selection method for induced pluripotent stem cells, and production method for induced pluripotent stem cells |
WO2018135646A1 (en) | 2017-01-20 | 2018-07-26 | 国立大学法人京都大学 | METHOD FOR PRODUCING CD8α+β+ CYTOTOXIC T CELLS |
WO2018139548A1 (en) | 2017-01-26 | 2018-08-02 | 国立大学法人大阪大学 | Medium for inducing differentiation of stem cells into mesodermal cells and method for producing mesodermal cells |
US10071094B2 (en) | 2014-07-24 | 2018-09-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes |
WO2018168829A1 (en) | 2017-03-14 | 2018-09-20 | 国立大学法人京都大学 | Method for producing helper t cells from pluripotent stem cells |
WO2018216743A1 (en) | 2017-05-25 | 2018-11-29 | 国立大学法人京都大学 | Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell |
US10149847B2 (en) | 2012-06-29 | 2018-12-11 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
WO2018235583A1 (en) | 2017-06-19 | 2018-12-27 | 公益財団法人神戸医療産業都市推進機構 | Method for predicting differentiation ability of pluripotent stem cell, and reagent for same |
EP2853592B1 (en) * | 2012-05-23 | 2019-02-20 | Kyoto University | Highly efficient method for establishing artificial pluripotent stem cell |
WO2019078263A1 (en) | 2017-10-17 | 2019-04-25 | 国立大学法人京都大学 | Method for obtaining artificial neuromuscular junction from pluripotent stem cells |
WO2020013315A1 (en) | 2018-07-13 | 2020-01-16 | 国立大学法人京都大学 | METHOD FOR PRODUCING γδ T CELLS |
WO2020017575A1 (en) | 2018-07-19 | 2020-01-23 | 国立大学法人京都大学 | Plate-shaped cartilage derived from pluripotent stem cells and method for producing plate-shaped cartilage |
WO2020022261A1 (en) | 2018-07-23 | 2020-01-30 | 国立大学法人京都大学 | Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same |
WO2020116606A1 (en) | 2018-12-06 | 2020-06-11 | キリンホールディングス株式会社 | Production method for t cells or nk cells, medium for culturing t cells or nk cells, method for culturing t cells or nk cells, method for maintaining undifferentiated state of undifferentiated t cells, and growth-accelerating agent for t cells or nk cells |
WO2020130147A1 (en) | 2018-12-21 | 2020-06-25 | 国立大学法人京都大学 | Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage |
WO2020138371A1 (en) | 2018-12-26 | 2020-07-02 | キリンホールディングス株式会社 | Modified tcr and production method therefor |
US10711249B2 (en) | 2014-12-26 | 2020-07-14 | Kyoto University | Method for inducing hepatocytes |
WO2020230832A1 (en) | 2019-05-15 | 2020-11-19 | 味の素株式会社 | Method for purifying neural crest cells or corneal epithelial cells |
WO2020235319A1 (en) | 2019-05-20 | 2020-11-26 | 味の素株式会社 | Expansion culture method for cartilage or bone precursor cells |
WO2021117886A1 (en) | 2019-12-12 | 2021-06-17 | 国立大学法人千葉大学 | Freeze-dried preparation containing megakaryocytes and platelets |
WO2021174004A1 (en) | 2020-02-28 | 2021-09-02 | Millennium Pharmaceuticals, Inc. | Method for producing natural killer cells from pluripotent stem cells |
WO2021256522A1 (en) | 2020-06-17 | 2021-12-23 | 国立大学法人京都大学 | Chimeric antigen receptor-expressing immunocompetent cells |
EP3929302A1 (en) | 2014-07-14 | 2021-12-29 | Chugai Seiyaku Kabushiki Kaisha | Method for identifying epitope on protein |
WO2022014604A1 (en) | 2020-07-13 | 2022-01-20 | 国立大学法人京都大学 | Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells |
WO2022019152A1 (en) | 2020-07-20 | 2022-01-27 | 学校法人 愛知医科大学 | Composition for undifferentiated maintenance culture of pluripotent cells, medium for undifferentiated maintenance culture of pluripotent cells, maintenance culture method in undifferentiated state of pluripotent cells, and method for producing pluripotent cells |
WO2022039279A1 (en) | 2020-08-18 | 2022-02-24 | 国立大学法人京都大学 | Method for maintaining and amplifying human primordial germ cells / human primordial germ cell-like cells |
US11401504B2 (en) | 2016-04-15 | 2022-08-02 | Kyoto University | Method for inducing antigen specific CD8 positive T cells |
WO2022196714A1 (en) | 2021-03-17 | 2022-09-22 | アステラス製薬株式会社 | Pericyte having basic fibroblast growth factor (bfgf) gene introduced therein |
WO2022230977A1 (en) | 2021-04-30 | 2022-11-03 | 国立研究開発法人理化学研究所 | Cord-like aggregates of retinal pigment epithelial cells, device and production method for producing same, and therapeutic agent comprising said cord-like aggregates |
WO2022255489A1 (en) | 2021-06-04 | 2022-12-08 | キリンホールディングス株式会社 | Cell composition, method for producing cell composition, and pharmaceutical composition containing cell composition |
WO2022259721A1 (en) | 2021-06-10 | 2022-12-15 | 味の素株式会社 | Method for producing mesenchymal stem cells |
WO2022264033A1 (en) | 2021-06-15 | 2022-12-22 | Takeda Pharmaceutical Company Limited | Method for producing natural killer cells from pluripotent stem cells |
WO2023286834A1 (en) | 2021-07-15 | 2023-01-19 | アステラス製薬株式会社 | Pericyte-like cell expressing vascular endothelial growth factor (vegf) at high level |
WO2023286832A1 (en) | 2021-07-15 | 2023-01-19 | アステラス製薬株式会社 | Pericyte-like cells expressing vascular endothelial growth factor (vegf) at high level |
WO2023017848A1 (en) | 2021-08-11 | 2023-02-16 | 国立大学法人京都大学 | Method for producing renal interstitial progenitor cells, erythropoietin-producing cells, and method for producing renin-producing cells |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190117663A1 (en) * | 2016-04-04 | 2019-04-25 | Case Western Reserve University | Compositions and methods for treating cancer |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2957906A (en) | 1955-10-25 | 1960-10-25 | Monsanto Chemicals | Ketones |
JPS5752354B2 (en) | 1973-10-22 | 1982-11-06 | ||
US3980674A (en) | 1974-01-28 | 1976-09-14 | Delmar Chemicals Limited | 2,3-Disubstituted 7-oxabicyclo-[2.2.1]-5-heptene |
JPS5132733A (en) | 1974-09-10 | 1976-03-19 | Kyowa Hakko Kogyo Kk | Josozai |
US3954913A (en) | 1975-01-06 | 1976-05-04 | The Standard Oil Company | Stabilized nitrile polymers |
JPS5188631A (en) | 1975-01-31 | 1976-08-03 | Hiiryoyosatsukinzai oyobi sonoseizoho | |
US4143054A (en) | 1977-11-04 | 1979-03-06 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane- and 7-oxabicycloheptene compounds |
US4218478A (en) | 1979-01-05 | 1980-08-19 | Ruiko Oiwa | Trichostatin as an antiprotozoal agent |
US4298752A (en) | 1980-09-19 | 1981-11-03 | Regents Of The University Of California | Cycloadduct precursors of cantharidin and method |
US4614825A (en) | 1982-05-17 | 1986-09-30 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane and 7-oxabicycloheptene compounds |
US4463015A (en) | 1982-08-18 | 1984-07-31 | E. R. Squibb & Sons, Inc. | Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation |
US4524151A (en) | 1983-11-14 | 1985-06-18 | E. R. Squibb & Sons, Inc. | 7-Oxabicycloheptane thio ethers useful as cardiovascular agents |
JPS61176523A (en) | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | Carcinostatic agent |
US4654355A (en) | 1985-08-01 | 1987-03-31 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane substituted amide-thioamide prostaglandin analogs |
US4816579A (en) | 1986-06-04 | 1989-03-28 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane amino-alcohol intermediates useful in making thromboxane A2 receptor antagonists |
US4851553A (en) | 1986-06-04 | 1989-07-25 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane amido-carboxylic acids |
US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
SU1553533A1 (en) | 1988-01-28 | 1990-03-30 | Военная Краснознаменная академия химической защиты им.Маршала Советского Союза С.К.Тимошенко | Method of producing 1,4-bispolyfluoroalkyl-7-oxabicyclo/2.2.1/heptanes |
JP2789365B2 (en) | 1988-12-14 | 1998-08-20 | 塩野義製薬株式会社 | Dicarboxylic acid monoester and production method thereof |
WO1991018891A1 (en) | 1990-06-04 | 1991-12-12 | Pfizer Inc. | Aromatic pyrrolidine and thiazolidine amides |
US5266710A (en) | 1990-12-18 | 1993-11-30 | Patel Ramesh N | (Exo,exo)-7-oxabicyclo[2.2.1]heptane-2,3-dimethanol; monoacyl ester and diacyl ester |
RU2015988C1 (en) | 1991-03-28 | 1994-07-15 | Тольяттинский политехнический институт | Modified synthetic isoprene rubber |
US5326898A (en) | 1992-02-11 | 1994-07-05 | Allergan, Inc. | Substituted phenylethenyl compounds having retinoid-like biological activity |
US5518993A (en) | 1994-08-12 | 1996-05-21 | Buckman Laboratories International, Inc. | Pesticidal compositions containing ethoxylated fatty amines for increasing the effectiveness of endothal and salts thereof |
US6222055B1 (en) | 1995-07-06 | 2001-04-24 | Fraunhofer-Gesellschaft Zur Foerderung Der Angwandten Forschung E.V. | Hydrolyzable and polymerizable and/or polyadditive silanes |
DE19600707B4 (en) | 1996-01-11 | 2004-02-19 | Glüsenkamp, Karl-Heinz, Dr. | Biyclic anhydride drug compounds, methods of making and using the same |
US5968965A (en) | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US5925651A (en) | 1996-04-03 | 1999-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6387673B1 (en) | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
PT1621077E (en) | 1997-10-15 | 2008-11-04 | Polarx Biopharmaceuticals Inc | Phamaceutical compositions comprising arsenic trioxide for the treatment of a tumor of the central nervous system |
AUPP466598A0 (en) | 1998-07-14 | 1998-08-06 | University Of Newcastle Research Associates Limited, The | Product and process |
US20040110822A1 (en) | 1998-07-14 | 2004-06-10 | The University Of Newcastle Research Associates | Anhydride modified cantharidin analogues useful in the treatment of cancer |
ATE329911T1 (en) | 1998-08-07 | 2006-07-15 | Applied Research Systems | FSH MIMETICS FOR THE TREATMENT OF INFERTILITY |
US20020151515A1 (en) | 1999-06-18 | 2002-10-17 | Roberts Bruce L. | Preparation and use of superior vaccines |
US6949624B1 (en) | 1999-08-03 | 2005-09-27 | The United States Of America As Represented By The Department Of Health And Human Services | Cloning of the human nuclear receptor co-repressor gene |
JP4518627B2 (en) | 2000-03-14 | 2010-08-04 | 旭化成イーマテリアルズ株式会社 | Hydroxy polyamide |
DE10038043B4 (en) | 2000-08-02 | 2006-09-07 | Walter, Michael, Dr. | Phamacologically active substance for the treatment of cardiovascular diseases |
PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
DE60112312T2 (en) | 2000-09-21 | 2005-12-29 | Smithkline Beecham P.L.C., Brentford | Imidazole Derivatives as RAF Kinase Inhibitors |
US6696483B2 (en) | 2000-10-03 | 2004-02-24 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
CN1213050C (en) | 2000-11-23 | 2005-08-03 | 拜尔公司 | Use of oxadicyclo [2.2.1] heptane derivative as pesticide |
US20020177692A1 (en) | 2001-04-16 | 2002-11-28 | Myriad Genetics, Incorporated | BCL-XL-interacting protein and use thereof |
AUPR392301A0 (en) | 2001-03-23 | 2001-04-26 | University Of Newcastle Research Associates Limited, The | Protein phosphatase inhibitors |
US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
US20070015144A9 (en) | 2001-05-25 | 2007-01-18 | Genset, S.A. | Human cDNAs and proteins and uses thereof |
US20040010045A1 (en) | 2001-09-07 | 2004-01-15 | Taolin Yi | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
CN100457183C (en) | 2001-11-06 | 2009-02-04 | 诺瓦提斯公司 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
EA013643B1 (en) | 2002-03-08 | 2010-06-30 | Басф Акциенгезельшафт | Fungicidal mixture based on protioconazole with thiamethoxam |
US6809118B2 (en) | 2002-07-25 | 2004-10-26 | Yih-Lin Chung | Methods for therapy of radiation cutaneous syndrome |
WO2003092616A2 (en) | 2002-05-01 | 2003-11-13 | The Cleveland Clinic Foundation | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
WO2003097835A2 (en) * | 2002-05-16 | 2003-11-27 | Molecular Engines Laboratories | Pharmaceutical compositions for the treatment of cancer |
KR20060010709A (en) | 2002-09-23 | 2006-02-02 | 쉐링 코포레이션 | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
ES2245619T1 (en) | 2002-11-05 | 2006-01-16 | The Regents Of The University Of California | PROCEDURES AND MATERIALS TO EXAMINE ROADS ASSOCIATED WITH THE PROGRESSION OF GLIOBLASTOMA. |
US20040197888A1 (en) | 2002-12-31 | 2004-10-07 | Armour Christopher D. | Alternatively spliced isoforms of histone deacetylase 3 (HDAC3) |
CA2518407A1 (en) | 2003-03-12 | 2004-09-23 | Samaritan Pharmaceuticals, Inc. | Animal model simulating neurologic disease |
US20050203082A1 (en) | 2003-08-13 | 2005-09-15 | Hsu Chung Y. | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents |
US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
WO2005018673A1 (en) | 2003-08-21 | 2005-03-03 | Osaka University | Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby |
US20070208166A1 (en) | 2003-10-24 | 2007-09-06 | Exelixis, Inc. | Tao Kinase Modulators And Method Of Use |
AU2004291102A1 (en) | 2003-11-13 | 2005-06-02 | Board Of Regents, The University Of Texas System | Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure |
GB0328157D0 (en) | 2003-12-04 | 2004-01-07 | Imp College Innovations Ltd | Compounds |
EP1699436A2 (en) | 2003-12-12 | 2006-09-13 | Myogen, Inc. | Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
US20050282893A1 (en) | 2004-01-30 | 2005-12-22 | Au Jessie L | Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors |
CA2555632A1 (en) | 2004-02-02 | 2005-08-18 | Myogen, Inc. | Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure |
US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
FR2872704B1 (en) | 2004-07-12 | 2007-11-02 | Laurent Schwartz | PLURITHERAPY AGAINST CANCER |
US8299083B2 (en) | 2004-08-17 | 2012-10-30 | The Johns Hopkins University | PDE5 inhibitor compositions and methods for treating cardiac indications |
GB0511266D0 (en) | 2005-06-02 | 2005-07-13 | Trust | Chemical compounds |
US20090220507A1 (en) | 2005-07-22 | 2009-09-03 | Sucharov Carmen C | Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure |
CN101282718A (en) | 2005-08-10 | 2008-10-08 | 诺瓦提斯公司 | Method of use of deacetylase inhibitors |
EP1963258A4 (en) | 2005-12-19 | 2011-06-29 | Methylgene Inc | Histone deacetylase inhibitors for enhancing activity of antifungal agents |
WO2007092414A2 (en) * | 2006-02-06 | 2007-08-16 | Lixte Biotechnology Holdings, Inc. | Use of phosphatases to treat tumors overexpressing n-cor |
AU2007234843B2 (en) | 2006-04-07 | 2013-07-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
US20090018142A9 (en) | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
TWI449524B (en) | 2006-09-07 | 2014-08-21 | Stemline Therapeutics Inc | Cancer therapy with cantharidin and cantharidin analogs |
WO2008028965A2 (en) | 2006-09-08 | 2008-03-13 | Institut Gustave Roussy | Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof |
AU2007321720A1 (en) | 2006-11-15 | 2008-05-22 | Genetic Technologies Limited | Compounds, compositions and methods for controlling invertebrate pests |
WO2008097561A1 (en) | 2007-02-06 | 2008-08-14 | Lixte Biotechology Holdings, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
AU2008284364A1 (en) * | 2007-08-03 | 2009-02-12 | Lixte Biotechnology, Inc. | Use of phosphatases to treat neuroblastomas and medulloblastomas |
CN101854804B (en) | 2007-10-01 | 2014-07-23 | 利克斯特生物技术公司 | Hdac inhibitors |
CA2730428A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
CA2730148C (en) | 2008-08-01 | 2018-04-03 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US20120135522A1 (en) | 2009-06-18 | 2012-05-31 | Kovach John S | Methods of modulating cell regulation by inhibiting p53 |
US20140235649A1 (en) | 2011-05-24 | 2014-08-21 | Lixte Biotechnology, Inc. | Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function |
AU2013282365A1 (en) | 2012-06-29 | 2015-02-19 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
WO2014005080A1 (en) | 2012-06-29 | 2014-01-03 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury |
WO2014137741A1 (en) | 2013-03-05 | 2014-09-12 | Lixte Biotechnology, Inc. | Hdac inhibitors for treating traumatic brain injury |
EP2968279A4 (en) | 2013-03-15 | 2016-09-28 | Lixte Biotechnology Inc | Sanguinarine analog pp2c inhibitors for cancer treatment |
CA2909160C (en) | 2013-04-09 | 2021-05-25 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
JP2016538281A (en) | 2013-11-15 | 2016-12-08 | リクスト・バイオテクノロジー,インコーポレイテッド | Protein phosphatase inhibitors that cross the blood-brain barrier |
EP3157336A4 (en) | 2014-06-20 | 2018-01-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer |
CN106572989B (en) | 2014-07-24 | 2021-08-27 | H·李·莫菲特癌症中心与研究所公司 | Protein phosphatase 2A inhibitors for the treatment of myelodysplastic syndrome |
CA2960989A1 (en) | 2014-09-12 | 2016-03-17 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
US9994584B2 (en) | 2014-10-15 | 2018-06-12 | Lixte Biotechnology, Inc. | Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid |
-
2010
- 2010-02-01 WO PCT/US2010/000279 patent/WO2010147612A1/en active Application Filing
-
2013
- 2013-04-25 US US13/870,763 patent/US9526915B2/en not_active Expired - Fee Related
-
2016
- 2016-12-20 US US15/385,357 patent/US20170259081A1/en not_active Abandoned
Non-Patent Citations (6)
Title |
---|
CHO ET AL.: "Crystal Structure of a Protein Phosphatase 2A Heterotrimeric holoenzyme.", NATURE, vol. 445, 2007, pages 53 - 57, XP002536049, DOI: doi:10.1038/NATURE05351 * |
DREESEN ET AL.: "Signaling Pathways in Cancer and Embryonic Stem Cells", STEM CELL REVIEWS AND REPORTS, vol. 3, 2007, pages 7 - 17 * |
HART ET AL.: "Modified norcantharidins: synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.", BIOORGANIC MEDICINAL CHEMISTRY LETTERS, vol. 14, 2004, pages 1969 - 1973, XP002624048, DOI: doi:10.1016/J.BMCL.2004.01.093 * |
SRIDHARAN ET AL.: "Illuminating the Black Box of Reprogramming.", CELL STEM CELL, vol. 2, 2008, pages 295 - 297, XP009104571, DOI: doi:10.1016/j.stem.2008.03.015 * |
STEWART ET AL.: "Synthesis and Biological Evaluation of Norcantharidin Analogues: Towards PP1 selectivity.", BIOORGANIC MEDICINAL CHEMISTRY, vol. 15, 2007, pages 7301 - 7310, XP022293931, DOI: doi:10.1016/j.bmc.2007.08.028 * |
YAN ET AL.: "Inhibition of Protein Phosphatase Activity Induces p53-Dependent Apoptosis in the Absence of p53 Transactivation.", JOURNAL BIOLOGICAL CHEMISTRY, vol. 272, 1997, pages 15220 - 15226, XP002224869, DOI: doi:10.1074/jbc.272.24.15220 * |
Cited By (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10399993B2 (en) | 2007-02-06 | 2019-09-03 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US9079917B2 (en) | 2007-02-06 | 2015-07-14 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US10023587B2 (en) | 2007-02-06 | 2018-07-17 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US8455688B2 (en) | 2007-10-01 | 2013-06-04 | Lixte Biotechnology, Inc. | HDAC inhibitors |
US8541458B2 (en) | 2008-08-01 | 2013-09-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US9526915B2 (en) | 2008-08-01 | 2016-12-27 | John S. Kovach | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
EP3305899A1 (en) | 2011-07-25 | 2018-04-11 | Kyoto University | Method for screening induced pluripotent stem cells |
EP3608423A1 (en) | 2011-07-25 | 2020-02-12 | Kyoto University | Method for screening induced pluripotent stem cells |
WO2013058403A1 (en) | 2011-10-21 | 2013-04-25 | 国立大学法人京都大学 | Method for culturing pluripotency-maintained singly dispersed cells by means of laminar flow |
WO2013077423A1 (en) | 2011-11-25 | 2013-05-30 | 国立大学法人京都大学 | Method for culturing pluripotent stem cell |
CN102533828A (en) * | 2011-12-23 | 2012-07-04 | 苏州大学附属第一医院 | Recombinant plasmid and virus of tissue specificity and application thereof. |
US10519425B2 (en) | 2012-05-23 | 2019-12-31 | Kyoto University | Highly efficient method for establishing induced pluripotent stem cell |
EP2853592B1 (en) * | 2012-05-23 | 2019-02-20 | Kyoto University | Highly efficient method for establishing artificial pluripotent stem cell |
US10149847B2 (en) | 2012-06-29 | 2018-12-11 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
US10668062B2 (en) | 2012-06-29 | 2020-06-02 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
WO2014123242A1 (en) | 2013-02-08 | 2014-08-14 | 国立大学法人京都大学 | Production methods for megakaryocytes and platelets |
WO2014136581A1 (en) | 2013-03-06 | 2014-09-12 | 国立大学法人京都大学 | Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells |
WO2014148646A1 (en) | 2013-03-21 | 2014-09-25 | 国立大学法人京都大学 | Pluripotent stem cell for neuronal differentiation induction |
WO2014157257A1 (en) | 2013-03-25 | 2014-10-02 | 公益財団法人先端医療振興財団 | Cell sorting method |
WO2014168941A1 (en) | 2013-04-09 | 2014-10-16 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
US10532050B2 (en) | 2013-04-09 | 2020-01-14 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
US11931354B2 (en) | 2013-04-09 | 2024-03-19 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
WO2014168264A1 (en) | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | Method for inducing alveolar epithelium progenitor cells |
WO2014185358A1 (en) | 2013-05-14 | 2014-11-20 | 国立大学法人京都大学 | Efficient myocardial cell induction method |
WO2014192909A1 (en) | 2013-05-31 | 2014-12-04 | iHeart Japan株式会社 | Layered cell sheet incorporating hydrogel |
WO2014200115A1 (en) | 2013-06-11 | 2014-12-18 | 国立大学法人京都大学 | Method for producing renal precursor cells, and drug containing renal precursor cells |
WO2015020113A1 (en) | 2013-08-07 | 2015-02-12 | 国立大学法人京都大学 | Method for producing pancreatic hormone-producing cell |
US9796962B2 (en) | 2013-08-07 | 2017-10-24 | Kyoto University | Method for generating pancreatic hormone-producing cells |
WO2015034012A1 (en) | 2013-09-05 | 2015-03-12 | 国立大学法人京都大学 | New method for inducing dopamine-producing neural precursor cells |
WO2015064754A1 (en) | 2013-11-01 | 2015-05-07 | 国立大学法人京都大学 | Novel chondrocyte induction method |
EP3929302A1 (en) | 2014-07-14 | 2021-12-29 | Chugai Seiyaku Kabushiki Kaisha | Method for identifying epitope on protein |
US10071094B2 (en) | 2014-07-24 | 2018-09-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes |
US10434100B2 (en) | 2014-07-24 | 2019-10-08 | Lixte Biotechnology, Inc. | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes |
US10711249B2 (en) | 2014-12-26 | 2020-07-14 | Kyoto University | Method for inducing hepatocytes |
US10413541B2 (en) | 2015-02-19 | 2019-09-17 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders |
US9833450B2 (en) | 2015-02-19 | 2017-12-05 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders |
EP3081638A1 (en) | 2015-04-16 | 2016-10-19 | Kyoto University | Method for producing pseudo-islets |
US10364252B2 (en) | 2015-05-15 | 2019-07-30 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs |
US11866444B2 (en) | 2015-05-15 | 2024-01-09 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs |
US9988394B2 (en) | 2015-05-15 | 2018-06-05 | Lixte Biotechnology Inc. | Oxabicycloheptane prodrugs |
US11236102B2 (en) | 2015-05-15 | 2022-02-01 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs |
US10618908B2 (en) | 2015-05-15 | 2020-04-14 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs |
US11401504B2 (en) | 2016-04-15 | 2022-08-02 | Kyoto University | Method for inducing antigen specific CD8 positive T cells |
WO2017183736A1 (en) | 2016-04-22 | 2017-10-26 | 国立大学法人京都大学 | Method for producing dopamine-producing neural precursor cells |
WO2018124118A1 (en) | 2016-12-27 | 2018-07-05 | 住友化学株式会社 | Evaluation method and selection method for induced pluripotent stem cells, and production method for induced pluripotent stem cells |
WO2018135646A1 (en) | 2017-01-20 | 2018-07-26 | 国立大学法人京都大学 | METHOD FOR PRODUCING CD8α+β+ CYTOTOXIC T CELLS |
EP4053268A2 (en) | 2017-01-20 | 2022-09-07 | Kyoto University | Method for producing cd8alpha+beta+cytotoxic t cells |
WO2018139548A1 (en) | 2017-01-26 | 2018-08-02 | 国立大学法人大阪大学 | Medium for inducing differentiation of stem cells into mesodermal cells and method for producing mesodermal cells |
WO2018168829A1 (en) | 2017-03-14 | 2018-09-20 | 国立大学法人京都大学 | Method for producing helper t cells from pluripotent stem cells |
WO2018216743A1 (en) | 2017-05-25 | 2018-11-29 | 国立大学法人京都大学 | Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell |
WO2018235583A1 (en) | 2017-06-19 | 2018-12-27 | 公益財団法人神戸医療産業都市推進機構 | Method for predicting differentiation ability of pluripotent stem cell, and reagent for same |
WO2019078263A1 (en) | 2017-10-17 | 2019-04-25 | 国立大学法人京都大学 | Method for obtaining artificial neuromuscular junction from pluripotent stem cells |
WO2020013315A1 (en) | 2018-07-13 | 2020-01-16 | 国立大学法人京都大学 | METHOD FOR PRODUCING γδ T CELLS |
WO2020017575A1 (en) | 2018-07-19 | 2020-01-23 | 国立大学法人京都大学 | Plate-shaped cartilage derived from pluripotent stem cells and method for producing plate-shaped cartilage |
WO2020022261A1 (en) | 2018-07-23 | 2020-01-30 | 国立大学法人京都大学 | Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same |
WO2020116606A1 (en) | 2018-12-06 | 2020-06-11 | キリンホールディングス株式会社 | Production method for t cells or nk cells, medium for culturing t cells or nk cells, method for culturing t cells or nk cells, method for maintaining undifferentiated state of undifferentiated t cells, and growth-accelerating agent for t cells or nk cells |
WO2020130147A1 (en) | 2018-12-21 | 2020-06-25 | 国立大学法人京都大学 | Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage |
WO2020138371A1 (en) | 2018-12-26 | 2020-07-02 | キリンホールディングス株式会社 | Modified tcr and production method therefor |
WO2020230832A1 (en) | 2019-05-15 | 2020-11-19 | 味の素株式会社 | Method for purifying neural crest cells or corneal epithelial cells |
WO2020235319A1 (en) | 2019-05-20 | 2020-11-26 | 味の素株式会社 | Expansion culture method for cartilage or bone precursor cells |
WO2021117886A1 (en) | 2019-12-12 | 2021-06-17 | 国立大学法人千葉大学 | Freeze-dried preparation containing megakaryocytes and platelets |
WO2021174004A1 (en) | 2020-02-28 | 2021-09-02 | Millennium Pharmaceuticals, Inc. | Method for producing natural killer cells from pluripotent stem cells |
WO2021256522A1 (en) | 2020-06-17 | 2021-12-23 | 国立大学法人京都大学 | Chimeric antigen receptor-expressing immunocompetent cells |
WO2022014604A1 (en) | 2020-07-13 | 2022-01-20 | 国立大学法人京都大学 | Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells |
WO2022019152A1 (en) | 2020-07-20 | 2022-01-27 | 学校法人 愛知医科大学 | Composition for undifferentiated maintenance culture of pluripotent cells, medium for undifferentiated maintenance culture of pluripotent cells, maintenance culture method in undifferentiated state of pluripotent cells, and method for producing pluripotent cells |
WO2022039279A1 (en) | 2020-08-18 | 2022-02-24 | 国立大学法人京都大学 | Method for maintaining and amplifying human primordial germ cells / human primordial germ cell-like cells |
WO2022196714A1 (en) | 2021-03-17 | 2022-09-22 | アステラス製薬株式会社 | Pericyte having basic fibroblast growth factor (bfgf) gene introduced therein |
WO2022230977A1 (en) | 2021-04-30 | 2022-11-03 | 国立研究開発法人理化学研究所 | Cord-like aggregates of retinal pigment epithelial cells, device and production method for producing same, and therapeutic agent comprising said cord-like aggregates |
WO2022255489A1 (en) | 2021-06-04 | 2022-12-08 | キリンホールディングス株式会社 | Cell composition, method for producing cell composition, and pharmaceutical composition containing cell composition |
WO2022259721A1 (en) | 2021-06-10 | 2022-12-15 | 味の素株式会社 | Method for producing mesenchymal stem cells |
WO2022264033A1 (en) | 2021-06-15 | 2022-12-22 | Takeda Pharmaceutical Company Limited | Method for producing natural killer cells from pluripotent stem cells |
WO2023286834A1 (en) | 2021-07-15 | 2023-01-19 | アステラス製薬株式会社 | Pericyte-like cell expressing vascular endothelial growth factor (vegf) at high level |
WO2023286832A1 (en) | 2021-07-15 | 2023-01-19 | アステラス製薬株式会社 | Pericyte-like cells expressing vascular endothelial growth factor (vegf) at high level |
WO2023017848A1 (en) | 2021-08-11 | 2023-02-16 | 国立大学法人京都大学 | Method for producing renal interstitial progenitor cells, erythropoietin-producing cells, and method for producing renin-producing cells |
Also Published As
Publication number | Publication date |
---|---|
US20130280210A1 (en) | 2013-10-24 |
US9526915B2 (en) | 2016-12-27 |
US20170259081A1 (en) | 2017-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010147612A1 (en) | Methods of modulating cell regulation by inhibiting p53 | |
US20120135522A1 (en) | Methods of modulating cell regulation by inhibiting p53 | |
US8124652B2 (en) | Use of parthenolide derivatives as antileukemic and cytotoxic agents | |
KR100802367B1 (en) | 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases | |
KR102124392B1 (en) | Compounds for the treatment of mtor pathway related diseases | |
TW200838540A (en) | Sulfamoyl-containing derivatives and uses thereof | |
HN1997000046A (en) | INDAZOL SUBSTITUTE DERIVATIVES AND RELATED COMPOUNDS | |
CN102958928A (en) | Dimeric SMAC Mimetics | |
JP2007535525A (en) | Pharmaceutical compositions containing β-carboline derivatives and their use for treating cancer | |
WO2010054253A1 (en) | Triazine derivatives as inhibitors of phosphodiesterases | |
US20230113478A1 (en) | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | |
EP3453393A1 (en) | Novel quinazolinone derivatives inhibiting pi3k and pharmaceutical composition containing same | |
WO2022086986A1 (en) | Treatment of hematological malignancies with inhibitors of menin | |
AU2015270125A1 (en) | Naphthyridinedione derivatives | |
HUE028525T2 (en) | 6-cycloamino-3-(1h-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives,preparation thereof and therapeutic use thereof | |
CA3102434C (en) | Selective a2a receptor antagonist | |
US20240051930A1 (en) | Heteroaromatic spermidine analogues and their anticancer activity | |
CN111377925B (en) | Purine derivatives, preparation method thereof and application thereof in medicines | |
AU2017280412A1 (en) | Substituted pyrrolo (2, 3-D) pyridazin-4-ones and pyrazolo (3, 4-D) pyridazin-4-ones as protein kinase inhibitors | |
KR20220140731A (en) | Polycyclic compounds acting as kinase inhibitors | |
CN116903609A (en) | Compound, pharmaceutical composition containing same and application of compound | |
CA3209234A1 (en) | Heteroaromatic phosphonium salts and their use treating cancer | |
CN118056835A (en) | Pyridazinones as PARP7 inhibitors | |
NZ727214B2 (en) | Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases | |
CN117487857A (en) | Modified nucleotide combination for enhancing antigen Survivin and/or human EGF receptor 2 and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10789837 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13378623 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10789837 Country of ref document: EP Kind code of ref document: A1 |